###begin article-title 0
TAK1 is an essential regulator of BMP signalling in cartilage
###end article-title 0
###begin p 1
These authors contributed equally to this work
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This license does not permit commercial exploitation without specific permission.
###end p 2
###begin p 3
###xml 205 212 202 209 <italic>in vivo</italic>
###xml 293 297 290 294 <italic>Tak1</italic>
###xml 333 337 330 334 <italic>Tak1</italic>
###xml 337 341 334 338 <sup>col2</sup>
###xml 604 608 601 605 <italic>Gdf5</italic>
###xml 932 939 929 936 <italic>in vivo</italic>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
TGFbeta activated kinase 1 (TAK1), a member of the MAPKKK family, controls diverse functions ranging from innate and adaptive immune system activation to vascular development and apoptosis. To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter. Tak1col2 mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion. This phenotype resembled that of bone morphogenetic protein receptor (BMPR)1 and Gdf5-deficient mice. BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases. TAK1 mediates Smad1 phosphorylation at C-terminal serine residues. These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways. Our experiments reveal an essential role for TAK1 in the morphogenesis, growth, and maintenance of cartilage.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 213 229 213 229 <xref ref-type="bibr" rid="b18">Kronenberg, 2003</xref>
###xml 231 251 231 251 <xref ref-type="bibr" rid="b45">Yoon and Lyons, 2004</xref>
###xml 382 387 382 387 <italic>et al</italic>
###xml 375 393 375 393 <xref ref-type="bibr" rid="b39">Wozney <italic>et al</italic>, 1988</xref>
###xml 602 622 602 622 <xref ref-type="bibr" rid="b45">Yoon and Lyons, 2004</xref>
###xml 756 761 756 761 <italic>et al</italic>
###xml 748 767 748 767 <xref ref-type="bibr" rid="b38">Winnier <italic>et al</italic>, 1995</xref>
###xml 1278 1292 1278 1292 <xref ref-type="bibr" rid="b21">Massague, 1998</xref>
###xml 1547 1570 1544 1567 <xref ref-type="bibr" rid="b6">Derynck and Zhang, 2003</xref>
###xml 729 734 <span type="species:ncbi:10090">mouse</span>
During endochondral ossification, mesenchymal stem cells undergo a highly organized differentiation program during which they condense and differentiate into chondrocytes, forming the template for bone formation (Kronenberg, 2003; Yoon and Lyons, 2004). Bone morphogenic proteins (BMPs) were originally isolated as proteins that promote ectopic cartilage and bone formation (Wozney et al, 1988). Further studies have confirmed the role of BMPs in cell proliferation, differentiation, and apoptosis during cartilage and bone formation and revealed additional functions in other developmental processes (Yoon and Lyons, 2004). For example, BMP-2 and BMP-4 are essential for the induction of ventral mesoderm formation during early mouse development (Winnier et al, 1995). BMP family members transduce signals through heteromeric complexes of type II and type I transmembrane serine/threoine kinase receptors. Type II receptor ligation initiates the recruitment of type I receptors to form heteromeric receptor complexes that are then transphosphorylated. The type I receptors in turn initiate Smad signalling by phosphorylating the receptor-regulated Smads, R-Smad1/5/8. Once phosphorylated, R-Smads associate with Smad4 and accumulate in the nucleus to regulate gene expression (Massague, 1998). In addition to the Smad-dependent pathway, BMPs can also activate TGFbeta activated kinase 1 (TAK1) leading to MKK3/6-mediated p38 MAP kinase activation. However, the mechanism by which TAK1 regulates BMP signalling in chondrocytes is largely unknown (Derynck and Zhang, 2003).
###end p 5
###begin p 6
###xml 158 163 155 160 <italic>et al</italic>
###xml 148 169 145 166 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 175 182 172 179 <italic>Xenopus</italic>
###xml 279 284 276 281 <italic>et al</italic>
###xml 271 290 268 287 <xref ref-type="bibr" rid="b31">Shibuya <italic>et al</italic>, 1998</xref>
###xml 316 320 313 317 <italic>Tak1</italic>
###xml 481 486 478 483 <italic>et al</italic>
###xml 475 492 472 489 <xref ref-type="bibr" rid="b5">Chang <italic>et al</italic>, 1999</xref>
###xml 499 504 496 501 <italic>et al</italic>
###xml 494 510 491 507 <xref ref-type="bibr" rid="b32">Shim <italic>et al</italic>, 2005</xref>
###xml 520 525 517 522 <italic>et al</italic>
###xml 512 531 509 528 <xref ref-type="bibr" rid="b12">Jadrich <italic>et al</italic>, 2006</xref>
###xml 650 657 647 654 <italic>in vivo</italic>
###xml 175 182 <span type="species:ncbi:8355">Xenopus</span>
###xml 310 315 <span type="species:ncbi:10090">mouse</span>
TAK1, a member of the MAPKKK family, was originally identified as a key regulator of MAPK kinase activation in TGFbeta and BMP signalling pathways (Yamaguchi et al, 1995). In Xenopus development, TAK1 mediates mesoderm induction and patterning downstream of BMP ligands (Shibuya et al, 1998). Mutations in the mouse Tak1 gene causes defects in the developing intraembryoinc vasculature and yolk sac, phenotypes similar to those caused by loss of function mutations in SMAD5 (Chang et al, 1999; Shim et al, 2005; Jadrich et al, 2006), suggesting that TAK1 may be important for Smad activation downstream of BMP stimulation. However, no biochemical or in vivo functional data currently exist to support this hypothesis.
###end p 6
###begin p 7
###xml 67 71 67 71 <italic>Tak1</italic>
###xml 365 370 358 363 <italic>et al</italic>
###xml 360 376 353 369 <xref ref-type="bibr" rid="b32">Shim <italic>et al</italic>, 2005</xref>
###xml 593 598 582 587 <italic>et al</italic>
###xml 588 604 577 593 <xref ref-type="bibr" rid="b27">Sato <italic>et al</italic>, 2005</xref>
###xml 606 610 595 599 <xref ref-type="bibr" rid="b28">2006</xref>
###xml 616 621 605 610 <italic>et al</italic>
###xml 612 627 601 616 <xref ref-type="bibr" rid="b19">Liu <italic>et al</italic>, 2006</xref>
###xml 633 638 622 627 <italic>et al</italic>
###xml 629 644 618 633 <xref ref-type="bibr" rid="b37">Wan <italic>et al</italic>, 2006</xref>
###xml 821 826 810 815 <italic>et al</italic>
###xml 815 832 804 821 <xref ref-type="bibr" rid="b24">Omori <italic>et al</italic>, 2006</xref>
###xml 841 846 830 835 <italic>et al</italic>
###xml 834 852 823 841 <xref ref-type="bibr" rid="b29">Sayama <italic>et al</italic>, 2006</xref>
###xml 976 981 961 966 <italic>et al</italic>
###xml 971 987 956 972 <xref ref-type="bibr" rid="b35">Tang <italic>et al</italic>, 2008</xref>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
Because of the early lethality of mice with a germline deletion of Tak1, cellular studies in these mice were limited to mouse embryonic fibroblasts (MEFs). TAK1-deficient MEFs displayed normal activation of canonical Smads after TGFbeta stimulation, despite displaying a block in NF-kappaB and JNK activation by microbial products in the innate immune system (Shim et al, 2005). TAK1 also has critical functions in the regulation of adaptive immunity where it is required for antigen receptor signalling in both T cells and B cells through its regulation of NF-kappaB and JNK activation (Sato et al, 2005, 2006; Liu et al, 2006; Wan et al, 2006). In addition to its role in the immune system, TAK1 functions as a key regulator of vascular development and keratinocyte proliferation, differentiation, and apoptosis (Omori et al, 2006; Sayama et al, 2006) and mediates survival of hematopoietic cells and hepatocytes through its regulation of NF-kappaB and JNK activation (Tang et al, 2008).
###end p 7
###begin p 8
###xml 252 256 249 253 <italic>Tak1</italic>
###xml 341 345 338 342 <italic>Tak1</italic>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
Given earlier studies suggesting a role for TAK1 in signalling downstream of both the BMP and TGFbeta signalling pathways and the importance of these pathways for chondrocyte biology, we decided to generate mice with cartilage-specific deletion of the Tak1 gene to address the physiological roles of mammalian TAK1 in cartilage. Deletion of Tak1 in chondrocytes resulted in a dramatic runting phenotype with chondrodysplasia and joint abnormalities similar to that seen in mice deficient in BMP signalling. Biochemical analysis of TAK1-deficient chondrocytes confirmed a defect in BMP signalling that unexpectedly resulted in impaired Smad1/5/8 activation in addition to defective p38/Jnk/Erk MAP kinase signalling. We provide the first evidence that TAK1 is required for the normal development and preservation of cartilage.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Expression of TAK1 in cartilage
###end title 10
###begin p 11
###xml 177 185 177 185 <xref ref-type="fig" rid="f1">Figure 1</xref>
###xml 673 696 673 696 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S1</xref>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
As the expression pattern for TAK1 in cartilage is unknown, we stained for TAK1 using immunohistochemistry (IHC) on coronal tibial sections from a postnatal day 20 (p20) mouse (Figure 1). TAK1 staining was largely restricted to prehypertrophic and hypertrophic chondrocytes. Hypertrophic chondrocytes from both the terminal growth plate and the area surrounding the secondary centre of ossification showed positive staining. Additionally, TAK1 expression in E16.5 embryos was examined. TAK1 is widely expressed in multiple embryonic cartilage tissues, including the chondroepiphyses of the long bones, the laryngeal and tracheal cartilage, and the developing frontal bone (Supplementary Figure S1).
###end p 11
###begin title 12
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Abnormal cartilage development in TAK1-deficient mice
###end title 12
###begin p 13
###xml 82 86 82 86 <italic>Tak1</italic>
###xml 119 123 119 123 <italic>Tak1</italic>
###xml 209 214 209 214 <italic>et al</italic>
###xml 197 220 197 220 <xref ref-type="bibr" rid="b25">Ovchinnikov <italic>et al</italic>, 2000</xref>
###xml 435 443 435 443 <xref ref-type="fig" rid="f1">Figure 1</xref>
###xml 542 546 542 546 <italic>Tak1</italic>
###xml 546 550 546 550 <sup>col2</sup>
###xml 645 654 645 654 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 732 736 732 736 <italic>Tak1</italic>
###xml 736 740 736 740 <sup>col2</sup>
###xml 886 895 886 895 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 898 902 898 902 <italic>Tak1</italic>
###xml 902 906 902 906 <sup>col2</sup>
###xml 1070 1100 1070 1100 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2A and B</xref>
###xml 1279 1283 1279 1283 <italic>Tak1</italic>
###xml 1283 1287 1283 1287 <sup>col2</sup>
###xml 1341 1350 1341 1350 <xref ref-type="fig" rid="f2">Figure 2B</xref>
###xml 1433 1437 1433 1437 <italic>Tak1</italic>
###xml 1437 1441 1437 1441 <sup>col2</sup>
###xml 1558 1562 1558 1562 <italic>Tak1</italic>
###xml 1562 1566 1562 1566 <sup>col2</sup>
###xml 1697 1706 1697 1706 <xref ref-type="fig" rid="f2">Figure 2B</xref>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 1442 1446 <span type="species:ncbi:10090">mice</span>
To determine the role of TAK1 in cartilage development, we generated mice lacking Tak1 in cartilage by intercrossing a Tak1 floxed-allele strain of mice with a type II collagen-cre deleter strain (Ovchinnikov et al, 2000). IHC for TAK1 expression confirmed deletion specifically in chondrocytes, with staining absent in both the terminal growth plate and the hypertrophic chondrocytes surrounding the secondary centre of ossification (Figure 1). Animals homozygous for the floxed allele expressing the cre transgene (hereafter referred to as Tak1col2 mice) displayed severe postnatal growth retardation culminating in death by 2-3 weeks of age (Figure 2A). As shown in Alizarin red S/Alcian blue stained skeletal preps of p20 mice, Tak1col2 mice showed proportional shortening of the long bones of the limbs, a 'doming' of the cranium, malocclusion, and kyphosis of the thoracic spine (Figure 2A). Tak1col2 postnatal day 0 (p0) offspring showed a modest reduction in the length of long bones and disorganization of proliferating chondrocyte columns in the growth plate (Supplementary Figure S2A and B). Animals heterozygous for the floxed allele expressing the cre transgene showed no appreciable phenotype at any age (data not shown). Histologic analysis of coronal sections of Tak1col2 tibias confirmed a marked reduction in overall size (Figure 2B). Additionally, the formation of secondary ossification centres was delayed, with Tak1col2 mice showing only minimal vascular invasion and calcification within the secondary centre of ossification. Notably, Tak1col2 chondrocytes surrounding the secondary ossification centre progressed normally through the hypertrophic stage of differentiation (Figure 2B, arrow).
###end p 13
###begin p 14
###xml 45 49 45 49 <italic>Tak1</italic>
###xml 49 53 49 53 <sup>col2</sup>
###xml 141 148 141 148 <italic>in situ</italic>
###xml 255 279 255 279 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S2C</xref>
###xml 285 289 285 289 <italic>Tak1</italic>
###xml 289 293 289 293 <sup>col2</sup>
###xml 601 608 601 608 <italic>in situ</italic>
###xml 732 741 728 737 <xref ref-type="fig" rid="f2">Figure 2C</xref>
###xml 1032 1036 1028 1032 <italic>Tak1</italic>
###xml 1036 1040 1032 1036 <sup>col2</sup>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 1041 1045 <span type="species:ncbi:10090">mice</span>
To determine whether the runting observed in Tak1col2 mice is the result of a delay in endochondral ossification of long bones, we performed in situ hybridization for osteopontin on femurs from E16.5 embryos to highlight the ossified portion of the bone (Supplementary Figure S2C). As Tak1col2 embryos displayed a similar extent of ossification, it is unlikely that the runting phenotype observed postnatally is the result of defects in the early stages of endochondral ossification. The long bones of E18.5 embryos were similarly of comparable length to wild-type controls (data not shown). Finally, in situ hybridization of Collagen Xalpha (ColX) was performed to determine the effects of TAK1 deletion on chondrocyte maturation (Figure 2C). Although p20 mice displayed a moderate reduction in the size of the prehypertrophic/hypertrophic zone of ColX-positive chondrocytes, E16.5 and E18.5 embryos were found to display normal growth plate architecture. Taken together, these data indicate that the runting phenotype observed in Tak1col2 mice has an onset sometime between E18.5 and birth.
###end p 14
###begin p 15
###xml 41 45 41 45 <italic>Tak1</italic>
###xml 45 49 45 49 <sup>col2</sup>
###xml 204 208 204 208 <italic>Tak1</italic>
###xml 208 212 208 212 <sup>col2</sup>
###xml 433 442 433 442 <xref ref-type="fig" rid="f2">Figure 2D</xref>
###xml 445 449 445 449 <italic>Tak1</italic>
###xml 449 453 449 453 <sup>col2</sup>
The overall reduction in the size of the Tak1col2 chondroepiphysis could be due to increased chondrocyte apoptosis or decreased chondrocyte proliferation. To determine the relative contributions of each, Tak1col2 chondroepiphyses were stained for proliferating cell nuclear antigen (PCNA) as an index of cell proliferation and by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) as a marker for apoptotic cells (Figure 2D). Tak1col2 chondroepiphyses displayed both a decrease in chondrocyte proliferation in the prehypertrophic/proliferating zone of the growth plate and an increase in the apoptosis of terminal hypertrophic chondrocytes, indicating that both mechanisms contribute to the decrease in the size of the chondroepiphysis.
###end p 15
###begin p 16
###xml 102 106 102 106 <italic>Tak1</italic>
###xml 106 110 106 110 <sup>col2</sup>
###xml 117 126 117 126 <xref ref-type="fig" rid="f2">Figure 2E</xref>
###xml 405 414 393 402 <xref ref-type="fig" rid="f2">Figure 2E</xref>
###xml 621 630 609 618 <xref ref-type="fig" rid="f2">Figure 2F</xref>
###xml 1014 1023 1002 1011 <xref ref-type="fig" rid="f2">Figure 2F</xref>
###xml 1139 1143 1127 1131 <italic>Tak1</italic>
###xml 1143 1147 1131 1135 <sup>col2</sup>
###xml 1524 1528 1512 1516 <italic>Tak1</italic>
###xml 1528 1532 1516 1520 <sup>col2</sup>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 1533 1537 <span type="species:ncbi:10090">mice</span>
Radiographs revealed dislocation of the elbow and a corresponding lateral deviation of the forearm in Tak1col2 mice (Figure 2E, upper panels). The penetrance of this phenotype was approximately80% by two weeks of age. Alizarin red/alcian blue stained skeletal preparations of the elbow showed a similar disruption of the elbow architecture with the formation of ectopic calcifications in the joint space (Figure 2E, lower panels). Tissue sections taken parallel to the long axis of the forelimb showed that this phenotype corresponds with an overgrowth of the articular cartilage on the distal humerus facing the radius (Figure 2F, upper panels). The proximal end of the radius has expanded extensively around the protruding articular cartilage of the humerus to the point of displacing the normal articulation between the ulna and the distal humerus. To determine whether the elbow phenotype observed postnatally represents a developmental defect in joint formation, we examined the elbow joint of E14.5 embryos (Figure 2F, lower panels). The distal humerus and the proximal radius were present as a single continuous skeletal element in Tak1col2 embryos, whereas control embryos showed a clear cavitation of the joint and a separation of the two skeletal elements. Cavitation of the joint between the humerus and the ulna occurred normally (data not shown). Considering that histologic analysis of the p20 elbow joint shows the presence of a joint space between the distal humerus and proximal radius, this indicates that Tak1col2 mice display a delay in cavitation of the humero-radial joint space.
###end p 16
###begin p 17
###xml 72 81 72 81 <xref ref-type="fig" rid="f2">Figure 2G</xref>
###xml 459 463 459 463 <italic>Tak1</italic>
###xml 463 467 463 467 <sup>col2</sup>
###xml 715 719 715 719 <italic>Tak1</italic>
###xml 719 723 719 723 <sup>col2</sup>
###xml 1004 1009 1004 1009 <italic>et al</italic>
###xml 998 1015 998 1015 <xref ref-type="bibr" rid="b34">Storm <italic>et al</italic>, 1994</xref>
###xml 379 384 <span type="species:ncbi:10090">mouse</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 974 978 <span type="species:ncbi:10090">mice</span>
In addition, as shown in the high-power views of skeletal preparations (Figure 2G), the phalanges of the hindlimbs show a marked medial deviation and the tarsals show a failure to separate during development, the cuboid, lateral cuneiform, intermediate cuneiform, navicular, and calcaneus all forming a continuous skeletal element. Although the tarsals of the littermate control mouse show complete ossification by 20 days of age, the fused tarsal element of Tak1col2 mice shows incomplete ossification with a layer of Alcian blue positive cartilage surrounding the ossified centre. In contrast, the hip, shoulder, and temperomandibular joints showed no signs of developmental abnormalities (data not shown). Thus, Tak1col2 mice show both impaired growth of skeletal elements and defects in the elbow and tarsal joints. In this respect, they resemble a mixture of the tarsal and elbow abnormalities observed in GDF5-deficient mice and the long bone abnormalities present in mice lacking BMP 2/4/7 (Storm et al, 1994).
###end p 17
###begin title 18
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Reduced levels of BMP signalling in TAK1-deficient mice
###end title 18
###begin p 19
###xml 40 44 40 44 <italic>Tak1</italic>
###xml 44 48 44 48 <sup>col2</sup>
###xml 196 201 196 201 <italic>et al</italic>
###xml 191 207 191 207 <xref ref-type="bibr" rid="b46">Yoon <italic>et al</italic>, 2005</xref>
###xml 371 375 371 375 <italic>Tak1</italic>
###xml 375 380 375 380 <sup>fl/fl</sup>
###xml 385 389 385 389 <italic>Tak1</italic>
###xml 389 393 389 393 <sup>col2</sup>
###xml 499 503 499 503 <italic>Tak1</italic>
###xml 503 507 503 507 <sup>col2</sup>
###xml 514 523 514 523 <xref ref-type="fig" rid="f3">Figure 3A</xref>
###xml 690 694 690 694 <italic>Tak1</italic>
###xml 694 698 694 698 <sup>col2</sup>
###xml 755 764 755 764 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 776 780 776 780 <italic>Tak1</italic>
###xml 809 816 809 816 <italic>ex vivo</italic>
###xml 962 971 962 971 <xref ref-type="fig" rid="f3">Figure 3B</xref>
###xml 981 985 981 985 <italic>Tak1</italic>
###xml 1044 1051 1044 1051 <italic>in vivo</italic>
###xml 1440 1447 1437 1444 <italic>in vivo</italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
Overall phenotypic similarities between Tak1col2 mice and mice with specific deletions of multiple BMP receptor subunits in chondrocytes suggested a role for TAK1 in BMP signalling pathways (Yoon et al, 2005). To address this possibility directly, we performed immunostaining analysis for the phosphorylation of Smad 1/5/8 (BMP-responsive Smads) in the proximal tibia of Tak1fl/fl and Tak1col2 mice. Phosphorylation levels of Smad1/5/8 were significantly reduced in the hypertrophic chondrocytes of Tak1col2 mice (Figure 3A). Similarly, immunoblotting analysis of primary chondrocytes showed decreased basal levels of phosphorylated Smad 1/5/8 in TAK1-deficent chondrocytes derived from p0 Tak1col2 mice, as compared with littermate control chondrocytes (Figure 3B). However, Tak1 deletion did not affect the ex vivo basal phosphorylation levels of Smad2, and levels of Smad1 and Bmpr1A protein in TAK1-deficient chondrocytes were comparable to wt chondrocytes (Figure 3B). Hence, Tak1 deletion results in reduced levels of activated Smad1/5/8 in vivo implying that TAK1 may regulate BMP-responsive Smad activation (Smad1/5/8), but not TGFbeta-responsive Smad activation (Smad2). In addition, TAK1 appears to regulate Smad phosphorylation rather than altering expression of BMP signalling components. P38 is also known to be phosphorylated downstream of BMP stimulation; however, we were unable to determine phospho-p38 levels in cartilage in vivo by IHC, despite multiple attempts.
###end p 19
###begin p 20
###xml 38 45 38 45 <italic>in vivo</italic>
###xml 50 57 50 57 <italic>ex vivo</italic>
###xml 117 121 117 121 <italic>Tak1</italic>
###xml 121 125 121 125 <sup>col2</sup>
###xml 188 195 188 195 <italic>in vivo</italic>
###xml 352 368 352 368 <xref ref-type="bibr" rid="b18">Kronenberg, 2003</xref>
###xml 610 615 610 615 <italic>et al</italic>
###xml 601 621 601 621 <xref ref-type="bibr" rid="b9">Grimsrud <italic>et al</italic>, 2001</xref>
###xml 628 633 628 633 <italic>et al</italic>
###xml 623 639 623 639 <xref ref-type="bibr" rid="b47">Yoon <italic>et al</italic>, 2006</xref>
###xml 727 731 727 731 <italic>Tak1</italic>
###xml 731 735 731 735 <sup>col2</sup>
###xml 742 751 742 751 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 767 774 767 774 <italic>In situ</italic>
###xml 914 918 914 918 <italic>Tak1</italic>
###xml 918 922 918 922 <sup>col2</sup>
###xml 1034 1041 1034 1041 <italic>in vivo</italic>
###xml 1061 1068 1061 1068 <italic>in situ</italic>
###xml 1135 1144 1135 1144 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">Mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
As BMP signalling was reduced in both in vivo and ex vivo measurements of phosphorylated signalling intermediates in Tak1col2 mice, we examined expression levels of known BMP target genes in vivo. Indian hedgehog (IHH) is a key regulator of bone formation that coordinates both chondrocyte proliferation/differentiation and osteoblast differentiation (Kronenberg, 2003). Mice in which chondrocytes are genetically unable to respond to BMPs show decreased expression of IHH in prehypertrophic chondrocytes, and this is proposed as a major contributor to the limb growth retardation seen in these mice (Grimsrud et al, 2001; Yoon et al, 2006). We tested whether a similar reduction in IHH might contribute to the runting seen in Tak1col2 mice (Figure 3C, left panels). In situ hybridization of the proximal tibia with IHH probes showed a moderate decrease of IHH transcript levels in the hypertropic chondrocytes of Tak1col2 mice. To show that this reduction in IHH transcript levels resulted in a functional decrease in IHH signalling in vivo, we also performed in situ hybridization to quantify levels of the IHH target gene, patched (Figure 3C, left panels). Patched expression was reduced in both prehypertrophic chondrocytes and in the bone collar. The reduction in patched expression even outside of cartilage strongly suggests that TAK1 functions upstream of IHH expression in hypertrophic chondrocytes and not in signal transduction downstream of IHH.
###end p 20
###begin p 21
###xml 49 56 49 56 <italic>in vivo</italic>
###xml 71 78 71 78 <italic>in situ</italic>
###xml 129 132 129 132 <italic>Id1</italic>
###xml 179 206 179 206 <xref ref-type="bibr" rid="b23">Miyazono and Miyazawa, 2002</xref>
###xml 290 294 290 294 <italic>Tak1</italic>
###xml 294 298 294 298 <sup>col2</sup>
###xml 442 446 442 446 <italic>Tak1</italic>
###xml 535 544 535 544 <xref ref-type="fig" rid="f3">Figure 3C</xref>
###xml 619 626 619 626 <italic>in vivo</italic>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
To confirm a functional defect in BMP signalling in vivo, we performed in situ hybridization to measure the transcript levels of Id1, a known BMP target gene in multiple systems (Miyazono and Miyazawa, 2002). ID1 expression was almost completely ablated in the hypertrophic chondrocytes of Tak1col2 mice, whereas expression of type X collagen (ColX), the major extracelluar matrix marker for hypertrophic chondrocytes, was little affected by Tak1 deletion, showing only a modest reduction in the overall size of the hypertrophic zone (Figure 3C, right panels). These findings suggest that TAK1 is indispensable for the in vivo response to BMPs in the terminal growth plate.
###end p 21
###begin title 22
Impaired BMP signalling in TAK1-deficient chondrocytes
###end title 22
###begin p 23
###xml 112 115 112 115 <italic>Id1</italic>
###xml 117 121 117 121 <italic>Msx1</italic>
###xml 127 133 127 133 <italic>Noggin</italic>
###xml 142 147 142 147 <italic>et al</italic>
###xml 135 153 135 153 <xref ref-type="bibr" rid="b13">Kameda <italic>et al</italic>, 1999</xref>
###xml 155 182 155 182 <xref ref-type="bibr" rid="b23">Miyazono and Miyazawa, 2002</xref>
###xml 184 201 184 201 <xref ref-type="bibr" rid="b36">Wan and Cao, 2005</xref>
###xml 210 215 210 215 <italic>et al</italic>
###xml 203 221 203 221 <xref ref-type="bibr" rid="b4">Binato <italic>et al</italic>, 2006</xref>
###xml 353 362 353 362 <xref ref-type="fig" rid="f4">Figure 4A</xref>
BMP signalling through Smad1/5/8 is required for the induction of several canonical BMP target genes, including Id1, Msx1, and Noggin (Kameda et al, 1999; Miyazono and Miyazawa, 2002; Wan and Cao, 2005; Binato et al, 2006). We analysed the induction of these BMP target genes in primary TAK1-deficient chondrocytes by using a quantitative RT-PCR assay (Figure 4A). After activation by BMP2/7, wt but not TAK1-deficient chondrocytes showed an appreciable induction in levels of Id1, Msx1, and Noggin transcripts consistent with a role for TAK1 in mediating BMP-induced gene expression in chondrocytes.
###end p 23
###begin p 24
###xml 94 98 94 98 <italic>Tak1</italic>
###xml 98 103 98 103 <sup>fl/fl</sup>
###xml 108 112 108 112 <italic>Tak1</italic>
###xml 112 116 112 116 <sup>col2</sup>
###xml 204 209 204 209 <italic>et al</italic>
###xml 194 215 194 215 <xref ref-type="bibr" rid="b14">Kobayashi <italic>et al</italic>, 2005</xref>
###xml 222 227 222 227 <italic>et al</italic>
###xml 217 233 217 233 <xref ref-type="bibr" rid="b32">Shim <italic>et al</italic>, 2005</xref>
###xml 316 320 316 320 <italic>Tak1</italic>
###xml 320 324 320 324 <sup>col2</sup>
###xml 337 341 337 341 <italic>Tak1</italic>
###xml 341 346 341 346 <sup>fl/fl</sup>
###xml 361 385 361 385 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3A</xref>
###xml 403 407 403 407 <italic>Tak1</italic>
###xml 579 583 579 583 <italic>Tak1</italic>
###xml 583 587 583 587 <sup>col2</sup>
###xml 844 859 832 847 <xref ref-type="fig" rid="f4">Figure 4B and C</xref>
###xml 862 866 850 854 <italic>Tak1</italic>
###xml 866 871 854 859 <sup>fl/fl</sup>
###xml 988 992 976 980 <italic>Tak1</italic>
###xml 992 996 980 984 <sup>col2</sup>
###xml 1189 1198 1173 1182 <xref ref-type="fig" rid="f4">Figure 4B</xref>
###xml 1279 1283 1260 1264 <italic>Tak1</italic>
###xml 1382 1391 1360 1369 <xref ref-type="fig" rid="f4">Figure 4C</xref>
###xml 172 176 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
To facilitate further biochemical analysis, we immortalized primary chondrocytes derived from Tak1fl/fl and Tak1col2 newborn offspring by stably transfecting them with the SV40 large T antigen (Kobayashi et al, 2005; Shim et al, 2005). Immunoblotting for TAK1 confirmed a significant reduction in TAK1 expression in Tak1col2 relative to Tak1fl/fl chondrocytes (Supplementary Figure S3A). As deletion of Tak1 by col2-cre is not 100% efficient and chondrocytes were maintained as bulk cultures rather than colonies to avoid clonal artifacts, residual TAK1 expression is present in Tak1col2 chondrocyte cultures. We tested the requirement for TAK1 in BMP or TGFbeta signalling by measuring BMP/TGFbeta-dependent promoter activation. Cells were transfected with BMP or TGFbeta-responsive luciferase reporters and stimulated with BMP2/7 or TGFbeta (Figure 4B and C). Tak1fl/fl chondrocytes showed approximately two-fold induction in luciferase reporter activity in response to BMP2/7, whereas Tak1col2 chondrocytes showed no response. Similarly, overexpression of a catalytically inactive TAK1 mutant (DeltaN/K63W; hereafter CI) blocked gene induction in wt chondrocytes in response to BMP2/7 (Figure 4B, right panel). TGFbeta-induced luciferase reporter activity was not affected by Tak1 deletion, suggesting that, in chondrocytes, TAK1 is important for BMP but not TGFbeta signalling (Figure 4C).
###end p 24
###begin title 25
Reduced activation of Smad and MAP kinase pathways by BMPs in TAK1-deficient chondrocytes
###end title 25
###begin p 26
###xml 143 166 143 166 <xref ref-type="bibr" rid="b6">Derynck and Zhang, 2003</xref>
###xml 345 354 345 354 <xref ref-type="fig" rid="f4">Figure 4D</xref>
###xml 559 563 559 563 <italic>Tak1</italic>
###xml 712 736 712 736 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3C</xref>
###xml 739 743 739 743 <italic>Tak1</italic>
###xml 743 747 743 747 <sup>col2</sup>
###xml 943 958 943 958 <xref ref-type="fig" rid="f4">Figure 4D and E</xref>
###xml 1210 1234 1210 1234 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3D</xref>
It has been reported that BMP signalling is mediated by two distinct pathways: the canonical Smad pathway and the TAK1-p38 MAP kinase pathway (Derynck and Zhang, 2003). We examined the activation of these two arms of BMP signalling in TAK1-deficient chondrocytes by immunoblotting with antibodies specific for phospho-Smad1/5/8 and phospho-p38 (Figure 4D). In the absence of TAK1, Smad1/5/8 phosphorylation was moderately decreased, and a small, but reproducible decrease in the electrophoretic mobility of phosphorylated Smad proteins was detected. However, Tak1 deletion did not affect total Smad1 protein levels, implying that TAK1 regulates Smad phosphorylation rather than altering expression of Smad1/5/8 (Supplementary Figure S3C). Tak1col2 chondrocytes exhibited impaired activation of p38, Erk1/2, and Jnk1/2 MAP kinases in response to BMP2/7, implying that TAK1 may function as a key regulator of BMP-mediated MAP kinase activation (Figure 4D and E). Immunofluorescence staining for phospho-Smad1/5/8 after BMP2/7 stimulation showed that phosphorylated Smad1/5/8 was still able to translocate to the nucleus in the absence of TAK1, though the total levels of phosphorylated Smad1/5/8 were decreased (Supplementary Figure S3D).
###end p 26
###begin p 27
###xml 174 183 171 180 <xref ref-type="fig" rid="f4">Figure 4F</xref>
###xml 186 190 183 187 <italic>Tak1</italic>
###xml 190 194 187 191 <sup>col2</sup>
###xml 480 485 471 476 <italic>et al</italic>
###xml 470 491 461 482 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 498 503 489 494 <italic>et al</italic>
###xml 493 509 484 500 <xref ref-type="bibr" rid="b32">Shim <italic>et al</italic>, 2005</xref>
Next, we examined TGFbeta-induced activation of the canonical Smad and MAP kinase pathway in TAK1-deficient chondrocytes by immunoblotting for phospho-Smad2 and phospho-p38 (Figure 4F). Tak1col2 cells exhibited a significant decrease in TGFbeta-induced p38 phosphorylation, whereas Smad2 phosphorylation occurred normally. This is consistent with earlier studies showing a requirement for TAK1 in the MAP kinase but not the canonical Smad pathway downstream of TGFbeta (Yamaguchi et al, 1995; Shim et al, 2005). Taken together, these results suggest that TAK1 is important for the activation of both the canonical Smad (Smad1/5/8) and MAP kinase pathways downstream of BMP2/7, whereas downstream of TGFbeta, TAK1 is important for the activation of p38 MAP kinase but not Smad2.
###end p 27
###begin title 28
TAK1 mediates phosphorylation of Smad proteins
###end title 28
###begin p 29
###xml 53 57 53 57 <italic>Tak1</italic>
###xml 57 61 57 61 <sup>col2</sup>
###xml 423 447 423 447 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S3E</xref>
###xml 456 460 456 460 <italic>Tak1</italic>
The decreased levels of Smad1/5/8 phosphorylation in Tak1col2 chondrocytes might be explained by a requirement for TAK1 in the association of the bone morphogenetic protein receptor (BMPR) complex with phosphorylated Smad1/5/8. However, immunoprecipitation analysis showed that in TAK1-deficient chondrocytes, the interaction between BMPR1A and phosphorylated Smad1/5/8 occurs normally, 5-15 min postinduction with BMP2/7 (Supplementary Figure S3E). Thus, Tak1 deletion does not affect the stability of the interaction between the BMPR complex and phosphorylated Smad proteins.
###end p 29
###begin p 30
###xml 139 163 139 163 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S4A</xref>
###xml 426 434 426 434 <italic>in vitro</italic>
###xml 447 449 447 449 <sup>35</sup>
###xml 466 475 466 475 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 673 678 673 678 <italic>et al</italic>
###xml 664 684 664 684 <xref ref-type="bibr" rid="b10">Hoffmann <italic>et al</italic>, 2005</xref>
###xml 768 792 768 792 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S4B</xref>
###xml 858 866 858 866 <italic>in vitro</italic>
###xml 879 881 879 881 <sup>35</sup>
###xml 898 907 898 907 <xref ref-type="fig" rid="f5">Figure 5A</xref>
###xml 1199 1208 1199 1208 <xref ref-type="fig" rid="f5">Figure 5B</xref>
###xml 1352 1382 1352 1382 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S4C and D</xref>
###xml 1393 1398 1393 1398 <italic>et al</italic>
###xml 1385 1404 1385 1404 <xref ref-type="bibr" rid="b15">Komatsu <italic>et al</italic>, 2002</xref>
###xml 1415 1420 1415 1420 <italic>et al</italic>
###xml 1406 1426 1406 1426 <xref ref-type="bibr" rid="b10">Hoffmann <italic>et al</italic>, 2005</xref>
To test whether TAK1 interacts with Smad proteins, HEK293 cells were transfected with Flag-tagged Smad proteins along with HA-tagged TAK1 (Supplementary Figure S4A). When overexpressed, Smad1, 2, 4, 5, and 8 all interact with TAK1, although the Smad4 association was weak. To test for direct interactions between TAK1 and BMP-responsive Smad proteins, we performed a Flag pull down analysis with Flag-tagged Smad proteins and in vitro translated, 35S-labelled TAK1 (Figure 5A, upper panel). Under these conditions, TAK1 interacted directly with Smad1, 5, and 8 and this likely occurs through the conserved MH2 domain of Smad proteins as shown in an earlier study (Hoffmann et al, 2005). The TAK1 domain located between aa 200 and 300 is required for binding to Smad1 (Supplementary Figure S4B). This was confirmed by a GST pull down assay with GST-Smad1 and in vitro translated, 35S-labelled TAK1 (Figure 5A, lower panel). Importantly, analysis of endogenous TAK1 and Smad1 showed an association 5-15 min after stimulation with BMP2/7, kinetics similar to the rate of Smad1/5/8 phosphorylation indicating that TAK1 interacts with BMP-responsive Smad proteins in chondrocytes in an inducible manner (Figure 5B). In contrast, catalytically inactive TAK1 did not associate with Smad 1/5/8 although it did interact with TAB1, a known TAK1-binding protein (Supplementary Figure S4C and D) (Komatsu et al, 2002; Hoffmann et al, 2005). These results indicate that the kinase activity of TAK1 is necessary for its interactions with Smad proteins.
###end p 30
###begin p 31
###xml 144 152 144 152 <italic>In vitro</italic>
###xml 341 346 333 338 <italic>et al</italic>
###xml 331 352 323 344 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 420 429 412 421 <xref ref-type="fig" rid="f5">Figure 5C</xref>
###xml 974 982 952 960 <italic>in vitro</italic>
###xml 998 1007 976 985 <xref ref-type="fig" rid="f5">Figure 5D</xref>
###xml 1379 1388 1348 1357 <xref ref-type="fig" rid="f5">Figure 5E</xref>
###xml 1401 1406 1370 1375 <italic>et al</italic>
###xml 1391 1412 1360 1381 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 1602 1606 1571 1575 <italic>Tak1</italic>
###xml 1606 1610 1575 1579 <sup>col2</sup>
###xml 1723 1728 1689 1694 <italic>et al</italic>
###xml 1720 1734 1686 1700 <xref ref-type="bibr" rid="b44">Yi <italic>et al</italic>, 2000</xref>
###xml 1741 1746 1707 1712 <italic>et al</italic>
###xml 1736 1752 1702 1718 <xref ref-type="bibr" rid="b46">Yoon <italic>et al</italic>, 2005</xref>
###xml 1611 1615 <span type="species:ncbi:10090">mice</span>
###xml 1651 1655 <span type="species:ncbi:10090">mice</span>
As TAK1 interacts directly with Smad proteins after BMP stimulation, we tested whether TAK1 is able to induce phosphorylation of Smad proteins. In vitro kinase assays using HA-TAK1 immunoprecipitates from HEK293 cells transfected with HA-tagged constitutively active TAK1 (DeltaN) or catalytically inactive TAK1 (CI; DeltaN/K63W) (Yamaguchi et al, 1995) were incubated with recombinant GST, GST-Smad1, -Smad2, or -Mkk6 (Figure 5C). As expected, GST-Mkk6, a known TAK1 substrate, was phosphorylated by HA-TAK1 (DeltaN), but not HA-TAK1 (CI). Notably, GST-Smad1 and -Smad2 were also both phosphorylated by HA-TAK1 (DeltaN) but not HA-TAK1 (CI), indicating that TAK1 can phosphorylate Smad proteins. Given that TAK1 can bind and phosphorylate both Smad1 and Smad2, it may be important for Smad phosphorylation in both BMP and TGFbeta signalling pathways. To test this hypothesis, we analysed TAK1-mediated phosphorylation of Smad1 and 2 after BMP and TGFbeta stimulation using in vitro kinase assays (Figure 5D). Surprisingly, little GST-Smad2 phosphorylation was detected in response to TGFbeta, whereas GST-Smad1 was strongly phosphorylated with peak activity 15 min postinduction by BMP2/7. However, GST-Mkk6 was equivalently phosphorylated after stimulation with either TGFbeta or BMP2/7, indicating that TAK1 is similarly activated downstream of TGFbeta and BMP2/7 signalling (Figure 5E) (Yamaguchi et al, 1995). Thus, differences in the intrinsic activation status of TAK1 are unlikely to account for the selective phorphorylation of Smad1 and not Smad2 by endogenous TAK1. This may explain why the Tak1col2 mice bear a much greater resemblance to mice with defects in BMP but not TGFbeta signalling in chondrocytes (Yi et al, 2000; Yoon et al, 2005).
###end p 31
###begin title 32
Identification of TAK1 phosphorylation sites in Smad1
###end title 32
###begin p 33
###xml 182 191 182 191 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 584 593 580 589 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 818 826 814 822 <xref ref-type="table" rid="t1">Tables I</xref>
###xml 831 833 827 829 <xref ref-type="table" rid="t2">II</xref>
###xml 845 850 841 846 <italic>et al</italic>
###xml 836 856 832 852 <xref ref-type="bibr" rid="b11">Hoodless <italic>et al</italic>, 1996</xref>
###xml 871 876 867 872 <italic>et al</italic>
###xml 858 882 854 878 <xref ref-type="bibr" rid="b20">Macias-Silva <italic>et al</italic>, 1996</xref>
###xml 893 898 889 894 <italic>et al</italic>
###xml 884 904 880 900 <xref ref-type="bibr" rid="b1">Abdollah <italic>et al</italic>, 1997</xref>
###xml 918 923 914 919 <italic>et al</italic>
###xml 906 930 902 926 <xref ref-type="bibr" rid="b17">Kretzschmar <italic>et al</italic>, 1997b</xref>
###xml 1137 1146 1129 1138 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 1340 1364 1328 1352 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S4E</xref>
###xml 1593 1602 1581 1590 <xref ref-type="fig" rid="f6">Figure 6B</xref>
###xml 1614 1619 1602 1607 <italic>et al</italic>
###xml 1605 1625 1593 1613 <xref ref-type="bibr" rid="b10">Hoffmann <italic>et al</italic>, 2005</xref>
###xml 1858 1863 1846 1851 <italic>et al</italic>
###xml 1846 1870 1834 1858 <xref ref-type="bibr" rid="b17">Kretzschmar <italic>et al</italic>, 1997b</xref>
###xml 2057 2072 2041 2056 <xref ref-type="fig" rid="f6">Figure 6C and D</xref>
###xml 2314 2323 2298 2307 <xref ref-type="fig" rid="f4">Figure 4D</xref>
###xml 2483 2485 2467 2469 <italic>wt</italic>
###xml 2526 2535 2510 2519 <xref ref-type="fig" rid="f6">Figure 6D</xref>
Coomassie blue staining showed a slight mobility shift of the isolated Smad1 protein when co-expressed with TAK1, implying that TAK1 induces posttranslational modification of Smad1 (Figure 6A). To identify the TAK1-mediated phosphorylation sites in Smad1, we performed mass spectrometry analysis. HEK293 cells were transfected with Flag-Smad1 together with either vector control or constitutively active TAK1 (DeltaN), and immunoprecipitated using Flag-conjugated agarose. As Smad1 interacts with TAK1 through its MH2 domain, phosphopeptide analysis initially focused on this region (Figure 6A, lower panel). Mass spectrometry analysis revealed that, when co-expressed with TAK1, Smad1 is phosphorylated at C-terminal serines (S463 and S465), the same phosphorylation sites targeted by the BMP type I receptor kinase (Tables I and II) (Hoodless et al, 1996; Macias-Silva et al, 1996; Abdollah et al, 1997; Kretzschmar et al, 1997b). This is consistent with the immunoblotting analysis with anti-phospho-Smad1/5/8 (S463/S465, S426/S428) showing that Flag-Smad1 is phosphorylated at C-terminal serines in the presence of HA-TAK1 (DeltaN) (Figure 6B). BMPR1 was not detectable in co-immunoprecipitations with HA-TAK1 (DeltaN), making it unlikely that the S463/S465 phosphorylation observed was mediated by BMPR1 that co-purified with HA-TAK1 (Supplementary Figure S4E). TAK1-induced phosphorylation at C-terminal serines was weaker than phosphorylation by constitutively active BMPR1B (Q203D), implying that BMPR1B is able to phosphorylate Smad1 at C-terminal serines more efficiently than TAK1 (Figure 6B) (Hoffmann et al, 2005). To test the ability of TAK1 to induce Smad1 phosphorylation at C-terminal serines, we generated recombinant GST-Smad1 containing the SSVS to AAVA mutation, which is a poor substrate for the BMP type I receptor kinase (Kretzschmar et al, 1997b). Mutation of the S463/S465 site to AAVA led to a moderate decrease in TAK1 (DeltaN)-induced phosphorylation, although it significantly decreased BMPR1B (Q203D)-induced phosphorylation (Figure 6C and D). This is consistent with immunoblotting analysis with anti-phospho-Smad1/5/8 (S463/S465, S426/S428) showing that the phosphorylation level of Smad1 at S463/S465 was moderately decreased in TAK1-deficient chondrocytes in response to BMP2/7 (Figure 4D). Similarly, the AAVA mutated Smad1 only showed a partial reduction in the level of phosphorylation by the endogenous TAK1 complex immunoprecipitated from the wt chondrocyte line after BMP stimulation (Figure 6D). Thus, these results strongly suggest that TAK1 may phosphorylate Smad1 at sites in addition to S463/S465.
###end p 33
###begin title 34
Requirement of TAK1 kinase activity in BMP signalling
###end title 34
###begin p 35
###xml 171 179 171 179 <xref ref-type="fig" rid="f7">Figure 7</xref>
###xml 182 186 182 186 <italic>Tak1</italic>
###xml 186 190 186 190 <sup>col2</sup>
###xml 550 559 550 559 <xref ref-type="fig" rid="f7">Figure 7A</xref>
To test the absolute requirement for TAK1 kinase activity in BMP signalling, TAK1-deficient chondrocytes were reconstituted with exogenous TAK1 using a lentiviral system (Figure 7). Tak1col2 chondrocytes were infected with either wt or CI TAK1 lentiviruses and selected in puromycin-containing medium. As expected, TAK1 (WT)-expressing cells exhibited an increase in Smad1/5/8 and p38 MAP kinase phosphorylation in response to BMP2/7. In contrast, exogenous expression of catalytically inactive TAK1 (CI) failed to restore Smad1/5/8 phosphorylation (Figure 7A).
###end p 35
###begin p 36
###xml 37 41 37 41 <italic>Tak1</italic>
###xml 41 45 41 45 <sup>col2</sup>
###xml 208 212 208 212 <italic>Tak1</italic>
###xml 212 216 212 216 <sup>col2</sup>
###xml 231 258 231 258 <xref ref-type="bibr" rid="b23">Miyazono and Miyazawa, 2002</xref>
###xml 347 356 347 356 <xref ref-type="fig" rid="f7">Figure 7B</xref>
The functional response to BMP2/7 in Tak1col2 chondrocytes could also be reconstituted by TAK1 expression. Exogenous expression of TAK1 (WT) significantly increased ID1 expression after BMP2/7 stimulation of Tak1col2 chondrocytes (Miyazono and Miyazawa, 2002), whereas little induction of ID1 was detected in vector or TAK1 (CI)-expressing cells (Figure 7B). Therefore, TAK1 activates both the canonical Smad and the p38 MAP kinase pathways through its kinase activity, and this activity is important for the transcriptional response to BMP2/7.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 177 182 174 179 <italic>et al</italic>
###xml 167 188 164 185 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 233 240 230 237 <italic>Xenopus</italic>
###xml 340 347 337 344 <italic>in vivo</italic>
###xml 408 413 405 410 <italic>et al</italic>
###xml 400 419 397 416 <xref ref-type="bibr" rid="b31">Shibuya <italic>et al</italic>, 1998</xref>
###xml 535 542 532 539 <italic>in vivo</italic>
###xml 233 240 <span type="species:ncbi:8355">Xenopus</span>
TAK1, a MAP3K kinase family member, was originally identified as a key mediator of the p38 MAPK kinase pathway that was activated downstream of both TGFbeta and BMP4 (Yamaguchi et al, 1995). However, with the exception of a study in Xenopus demonstrating that TAK1 mediates ventral mesoderm induction and patterning downstream of BMPs, the in vivo role of TAK1 in BMP signalling remained unexplored (Shibuya et al, 1998). The involvement of BMPs in growth, patterning, and maintenance of cartilage made this organ system an attractive in vivo model to explore.
###end p 38
###begin p 39
###xml 128 133 128 133 <italic>et al</italic>
###xml 123 139 123 139 <xref ref-type="bibr" rid="b32">Shim <italic>et al</italic>, 2005</xref>
###xml 149 154 149 154 <italic>et al</italic>
###xml 141 160 141 160 <xref ref-type="bibr" rid="b12">Jadrich <italic>et al</italic>, 2006</xref>
###xml 251 255 251 255 <italic>Tak1</italic>
###xml 281 285 281 285 <italic>Tak1</italic>
###xml 319 324 319 324 <italic>et al</italic>
###xml 315 330 315 330 <xref ref-type="bibr" rid="b40">Xie <italic>et al</italic>, 2006</xref>
###xml 574 579 574 579 <italic>et al</italic>
###xml 568 585 568 585 <xref ref-type="bibr" rid="b34">Storm <italic>et al</italic>, 1994</xref>
###xml 590 595 590 595 <italic>et al</italic>
###xml 587 601 587 601 <xref ref-type="bibr" rid="b44">Yi <italic>et al</italic>, 2000</xref>
###xml 617 622 617 622 <italic>et al</italic>
###xml 603 628 603 628 <xref ref-type="bibr" rid="b3">Bandyopadhyay <italic>et al</italic>, 2006</xref>
###xml 656 660 656 660 <italic>Tak1</italic>
###xml 956 979 956 979 <xref ref-type="bibr" rid="b6">Derynck and Zhang, 2003</xref>
###xml 981 1001 981 1001 <xref ref-type="bibr" rid="b45">Yoon and Lyons, 2004</xref>
###xml 1153 1158 1153 1158 <italic>et al</italic>
###xml 1143 1164 1143 1164 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 1243 1247 1243 1247 <italic>Tak1</italic>
###xml 1247 1251 1247 1251 <sup>col2</sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
Early embryonic lethality in germline TAK1-deficient mice precluded genetic studies of mammalian TAK1 in skeletal biology (Shim et al, 2005; Jadrich et al, 2006). We took advantage of an earlier generated strain of mice with a conditional deletion of Tak1 to generate mice lacking Tak1 selectively in chondrocytes (Xie et al, 2006). TAK1 deficiency in chondrocytes caused a severe chondrodysplasia with runting, elbow dislocation, cartilage overgrowth, and tarsal fusion, abnormalities that are variously present in mice lacking BMPR1B, GDF5, or multiple BMP ligands (Storm et al, 1994; Yi et al, 2000; Bandyopadhyay et al, 2006). The observation that the Tak1 phenotype represents a mixture of BMP-associated phenotypes indicates that TAK1 serves an essential function downstream of multiple BMP family members. Signal transduction downstream of BMPs can be considered as a dichotomy between the activation of MAP kinase pathways and the canonical Smads (Derynck and Zhang, 2003; Yoon and Lyons, 2004). Earlier, TAK1 was largely considered as a proximal activator of the MAP kinase arm of signalling, without a clear role in Smad activation (Yamaguchi et al, 1995). However, the reduction in both Smad and p38/Jnk/Erk MAP kinase responses in Tak1col2 chondrocytes indicates that TAK1 has an important but distinct function in both signalling arms downstream of BMP2/7.
###end p 39
###begin title 40
###xml 22 26 22 26 <sup>col2</sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Comparison of the Tak1col2 phenotype to the phenotype of mice deficient for BMP signalling
###end title 40
###begin p 41
###xml 4 8 4 8 <italic>Tak1</italic>
###xml 8 12 8 12 <sup>col2</sup>
###xml 182 186 182 186 <italic>Tak1</italic>
###xml 186 190 186 190 <sup>col2</sup>
###xml 283 288 283 288 <italic>et al</italic>
###xml 277 294 277 294 <xref ref-type="bibr" rid="b48">Zhang <italic>et al</italic>, 2005</xref>
###xml 350 354 350 354 <italic>Tak1</italic>
###xml 354 358 354 358 <sup>col2</sup>
###xml 470 475 470 475 <italic>et al</italic>
###xml 465 481 465 481 <xref ref-type="bibr" rid="b47">Yoon <italic>et al</italic>, 2006</xref>
###xml 512 516 512 516 <italic>Tak1</italic>
###xml 516 520 516 520 <sup>col2</sup>
###xml 820 825 820 825 <italic>et al</italic>
###xml 814 831 814 831 <xref ref-type="bibr" rid="b34">Storm <italic>et al</italic>, 1994</xref>
###xml 836 841 836 841 <italic>et al</italic>
###xml 833 847 833 847 <xref ref-type="bibr" rid="b44">Yi <italic>et al</italic>, 2000</xref>
###xml 1562 1569 1550 1557 <italic>in vivo</italic>
###xml 1576 1581 1564 1569 <italic>et al</italic>
###xml 1571 1587 1559 1575 <xref ref-type="bibr" rid="b46">Yoon <italic>et al</italic>, 2005</xref>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 808 812 <span type="species:ncbi:10090">mice</span>
###xml 1074 1078 <span type="species:ncbi:10090">mice</span>
###xml 1165 1169 <span type="species:ncbi:10090">mice</span>
###xml 1256 1260 <span type="species:ncbi:10090">mice</span>
###xml 1479 1483 <span type="species:ncbi:10090">mice</span>
The Tak1col2 phenotype is not identical to that of any single member of the BMP signalling pathway. The degree of runting and the delay in secondary ossification centre formation in Tak1col2 mice resemble that seen in mice with a conditional deletion of Smad4 in chondrocytes (Zhang et al, 2005). Additionally, the magnitude of IHH downregulation in Tak1col2 hypertrophic chondrocytes is similar to that observed in both Smad4 and BMPR1A conditional knockout mice (Yoon et al, 2006). Hence, these aspects of the Tak1col2 phenotype may be due to dysregulation of Smad signalling downstream of BMPs. However, mice with a conditional deletion of Smad4 in chondrocytes do not display elbow dislocation or fusion of the tarsal bones. These features are reminiscent of the defects seen in BMPR1B and GDF5 knockout mice (Storm et al, 1994; Yi et al, 2000), suggesting that the GDF5 to BMPR1B signalling module that maintains the integrity of the elbow joint also uses TAK1 as a necessary signalling intermediate. The penetrance of the elbow dislocation phenotype in TAK1-deficient mice is higher (approximately80% by 2 weeks of age) than that observed in BMPR1B-deficient mice (23%). Combined with the earlier onset of the dislocation phenotype in TAK1-deficient mice, this finding suggests that BMPR1B may have partial functional redundancy with another receptor subunit acting upstream of TAK1. This receptor subunit is highly likely to be BMPR1A, but the severe cartilage defects in mice lacking both BMPR1A/B in cartilage make analysis of this redundancy difficult in vivo (Yoon et al, 2005).
###end p 41
###begin p 42
###xml 24 28 24 28 <italic>GDF5</italic>
###xml 33 37 33 37 <italic>Tak1</italic>
###xml 37 41 37 41 <sup>col2</sup>
###xml 118 123 118 123 <italic>et al</italic>
###xml 112 129 112 129 <xref ref-type="bibr" rid="b34">Storm <italic>et al</italic>, 1994</xref>
###xml 194 198 194 198 <italic>GDF5</italic>
###xml 326 330 326 330 <italic>GDF5</italic>
###xml 461 465 461 465 <italic>Tak1</italic>
###xml 465 469 465 469 <sup>col2</sup>
###xml 848 855 848 855 <italic>in vivo</italic>
###xml 969 973 969 973 <italic>Tak1</italic>
###xml 973 977 973 977 <sup>col2</sup>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
This similarity between GDF5 and Tak1col2 phenotypes is further supported by the finding of tarsal bone fusion (Storm et al, 1994). However, mice with a spontaneous loss-of-function mutation in GDF5 show only a slight shortening of the long bones, implicating other BMP family members upstream of TAK1. Additionally, although GDF5 mutant mice do have fusion of the tarsal bones, they do not display the marked medial deviation of the hindlimb phalanges seen in Tak1col2 mice, indicating that this deviation is not simply secondary to ankle bone malformation. As these aspects of the phenotype (elbow dislocation, tarsal fusion) are present in GDF5 and BMPR1B but not Smad4-deficent mice, they may be MAP kinase dependent. However, the role of the MAP kinase pathway in postnatal cartilage growth and development has not been explored as thoroughly in vivo as the role of the Smad pathway, making it difficult to examine the contribution of MAP kinase signalling to the Tak1col2 phenotype.
###end p 42
###begin title 43
###xml 77 81 77 78 <italic>&#946;</italic>
TAK1 mediates phosphorylation of Smad proteins downstream of BMPs but not TGFbeta
###end title 43
###begin p 44
###xml 418 422 412 416 <italic>Tak1</italic>
###xml 422 426 416 420 <sup>col2</sup>
###xml 439 444 433 438 <italic>et al</italic>
###xml 433 450 427 444 <xref ref-type="bibr" rid="b30">Serra <italic>et al</italic>, 1997</xref>
###xml 458 463 452 457 <italic>et al</italic>
###xml 452 469 446 463 <xref ref-type="bibr" rid="b2">Baffi <italic>et al</italic>, 2004</xref>
###xml 1062 1067 1047 1052 <italic>et al</italic>
###xml 1052 1073 1037 1058 <xref ref-type="bibr" rid="b42">Yamaguchi <italic>et al</italic>, 1995</xref>
###xml 1342 1347 1324 1329 <italic>et al</italic>
###xml 1331 1353 1313 1335 <xref ref-type="bibr" rid="b33">Sorrentino <italic>et al</italic>, 2008</xref>
###xml 1365 1370 1347 1352 <italic>et al</italic>
###xml 1355 1376 1337 1358 <xref ref-type="bibr" rid="b43">Yamashita <italic>et al</italic>, 2008</xref>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
The TAK1 phenotype is notable for the absence of specific features of mice genetically unable to respond to TGFbeta in chondrocytes. In particular, mice with a deletion of TGFbetaR2 in chondrocytes display abnormalities in the axial skeleton, including bifurcation of the xiphoid process, abnormal morphogenesis of the C1, C2 vertebrae, and malformation of the vertebral transverse processes, which are not present in Tak1col2 mice (Serra et al, 1997; Baffi et al, 2004). In our study, analysis of primary and transformed chondrocytes revealed that TAK1 is able to phosphorylate Smad proteins in response to BMP2/7 but not TGFbeta. However, Smad1 (a BMP-responsive Smad) and Smad2 (a TGFbeta-responsive Smad) can both be phosphorylated by overexpressed, constitutively active TAK1, indicating that TAK1 has an equivalent intrinsic ability to phosphorylate both substrates. Additionally, phosphorylation of MKK6 by TAK1 is similar after BMP2/7 and TGFbeta stimulation, indicating that the activation of TAK1 kinase is similar downstream of each ligand (Yamaguchi et al, 1995). Recently, it has been reported that the activated TGFbeta receptor 1 recruits TRAF6 to the receptor complex and subsequently induces ubiquitination of TRAF6 and promotes TRAF6 interaction with TAK1, thereby resulting in activation of p38/JNK MAP kinases (Sorrentino et al, 2008; Yamashita et al, 2008). However, the mechanism of TAK1-mediated p38 MAP kinase activation downstream of BMP signalling has not been explored. Given these observations, the most likely explanation for the selective involvement of TAK1 in Smad phosphorylation downstream of BMP but not TGFbeta stimulation is that another component of the TGFbeta receptor complex acts to block TAK1 access to Smad2. For such a mechanism to be effective, the active fraction of TAK1 must be sequestered at the TGFbeta receptor complex. Likewise, either the BMP receptor complex is permissive for TAK1 and Smad1/5/8 interactions or TAK1 is released from the receptor complex to phosphorylate Smad1/5/8 in the cytosol.
###end p 44
###begin title 45
TAK1-inducible phosphorylation of Smad1 at multiple sites
###end title 45
###begin p 46
###xml 93 100 93 100 <italic>in vivo</italic>
###xml 105 113 105 113 <italic>in vitro</italic>
###xml 317 325 317 325 <italic>in vitro</italic>
###xml 437 446 437 446 <xref ref-type="fig" rid="f6">Figure 6A</xref>
###xml 448 456 448 456 <xref ref-type="table" rid="t1">Tables I</xref>
###xml 461 463 461 463 <xref ref-type="table" rid="t2">II</xref>
###xml 752 759 752 759 <italic>in vivo</italic>
###xml 764 772 764 772 <italic>in vitro</italic>
###xml 881 885 881 885 <italic>Tak1</italic>
###xml 885 889 885 889 <sup>col2</sup>
###xml 933 946 933 946 <xref ref-type="fig" rid="f3">Figures 3A, B</xref>
###xml 951 953 951 953 <xref ref-type="fig" rid="f4">4D</xref>
###xml 1029 1034 1029 1034 <italic>et al</italic>
###xml 1017 1041 1017 1041 <xref ref-type="bibr" rid="b17">Kretzschmar <italic>et al</italic>, 1997b</xref>
###xml 1145 1152 1145 1152 <italic>in vivo</italic>
###xml 1157 1165 1157 1165 <italic>in vitro</italic>
The finding that phosphorylation levels of Smad1/5/8 at C-terminal serines were reduced both in vivo and in vitro in response to BMP stimulation suggested an unexpected role for TAK1 in regulating the activity of BMP-responsive Smads. As the immunoprecipitated TAK1 protein was able to phosphorylate Smad1 protein in in vitro kinase assays, we undertook a systematic analysis of Smad1 phosphorylation using a mass spectrometry approach (Figure 6A; Tables I and II). This analysis showed that phosphorylation of Smad1 at the C-terminal serines S463/S465 was increased by co-expression of constitutively active TAK1. Mutation of this site confirmed this finding, showing an approximately 40% reduction in TAK1-mediated phosphorylation. Additionally, our in vivo and in vitro data show that S463/S465 phosphorylation was moderately decreased in both hypertrophic chondrocytes and the Tak1col2 chondrocyte line after BMP2/7 stimulation (Figures 3A, B and 4D). As S463/S465 phosphorylation is critical for Smad1 activity (Kretzschmar et al, 1997b), a reduction in S463/S465 phosphorylation would explain the reduction in BMP signalling observed both in vivo and in vitro in TAK1-deficient chondrocytes. This implies that TAK1 may have a function in amplification of the signal from the BMP receptor by increasing phosphorylation at the same S463/S465 site targeted by the BMPR1 kinase activity.
###end p 46
###begin p 47
###xml 156 171 156 171 <xref ref-type="fig" rid="f6">Figure 6C and E</xref>
###xml 763 768 757 762 <italic>et al</italic>
###xml 751 775 745 769 <xref ref-type="bibr" rid="b16">Kretzschmar <italic>et al</italic>, 1997a</xref>
###xml 788 793 782 787 <italic>et al</italic>
###xml 777 799 771 793 <xref ref-type="bibr" rid="b7">Fuentealba <italic>et al</italic>, 2007</xref>
###xml 809 814 803 808 <italic>et al</italic>
###xml 801 820 795 814 <xref ref-type="bibr" rid="b26">Sapkota <italic>et al</italic>, 2007</xref>
The partial reduction in Smad1 phosphorylation observed in S463/S465 mutated Smad1 (AAVA Smad1) indicates that additional sites are phosphorylated by TAK1 (Figure 6C and E). Further, the absence of detectable phosphorylation sites in the MH1 and MH2 domain by the phosphopeptide analysis suggests that these additional sites might lie inside the linker region. Unfortunately, the lack of Trypsin and Lys-C cleavable sites precluded finding phosphorylation site in this region. It has been reported that the Smad1 linker region contains four MAPK phosphorylation sites and two Gsk3beta sites and MAPK and Gsk3beta phosphorylation of the linker region restricts Smad1 activity by recruiting the ubiquitin ligase Smurf1, leading to degradation of Smad1 (Kretzschmar et al, 1997a; Fuentealba et al, 2007; Sapkota et al, 2007). As phosphorylation of these sites is important for the regulation of FGF/BMP pathway crosstalk, it will be interesting to test the possibility that TAK1 is involved in the regulation of BMP signalling by FGF through its phosphorylation of those linker phosphorylation sites. However, the critical role of TAK1 in BMP signalling precludes an analysis of this crosstalk until a component of the MAPK cascade downstream of TAK1-mediated BMP signalling is identified.
###end p 47
###begin title 48
A model of BMP receptor complex assembly
###end title 48
###begin p 49
###xml 378 383 378 383 <italic>et al</italic>
###xml 370 389 370 389 <xref ref-type="bibr" rid="b31">Shibuya <italic>et al</italic>, 1998</xref>
###xml 401 406 401 406 <italic>et al</italic>
###xml 391 412 391 412 <xref ref-type="bibr" rid="b41">Yamaguchi <italic>et al</italic>, 1999</xref>
###xml 419 427 419 427 <italic>in vitro</italic>
###xml 599 625 599 625 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5A&#8211;C</xref>
###xml 767 791 767 791 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5D</xref>
Analysis of the associations among TAK1, BMPR1A, and the adaptor proteins XIAP and TAB1 suggests a mechanism for TAK1 recruitment to the BMP receptor complex. In BMP signalling pathways, X-linked inhibitor of apoptosis protein (XIAP) functions as an adapter protein that connects the BMPR complex with the TAB1-TAK1 complex through its association with TAB1 and BMPR1A (Shibuya et al, 1998; Yamaguchi et al, 1999). Our in vitro experiments demonstrate that BMPR1A binds to XIAP, XIAP in turn mediates the interaction between BMPR1A and TAB1, and TAB1 mediates the interaction between XIAP and TAK1 (Supplementary Figure S5A-C). As the interaction of BMPR1A with XIAP occurs normally in TAK1-deficient chondrocytes, TAK1 functions downstream of the BMPR-XIAP complex (Supplementary Figure S5D).
###end p 49
###begin p 50
###xml 193 202 193 202 <xref ref-type="fig" rid="f7">Figure 7C</xref>
Hence, we propose a model wherein BMPR1A is connected to the TAK1 complex (TAK1-TAB1) through XIAP, and TAK1 mediates canonical Smad and p38 MAP kinase activation downstream of BMP signalling (Figure 7C). On BMP stimulation, the activated BMPRI recruits Smad 1/5/8 directly, and the TAK1 complex (TAK1-TAB1) is recruited to the receptor by the adaptor XIAP. R-Smads can be phosphoryated by the type I BMPR and TAK1 at either S463/465 (Smad1/5) or S426/428 (Smad8). Activated R-Smads, in turn, bind to Smad4, translocate into the nucleus, and mediate BMP-responsive gene expression (i.e. IHH, ID1, Noggin, and Msx1). Alternatively, the TAK1 complex can activate the MKK3/6-p38 MAP kinase pathway.
###end p 50
###begin p 51
###xml 385 400 374 389 <xref ref-type="fig" rid="f4">Figure 4D and F</xref>
Our results do not exclude the possibility that TAK1 may participate in the regulation of other BMP signalling intermediates and other signalling pathways. Indeed, in TAK1-deficient chondrocytes, a decreased phosphorylation of p38 MAP kinase was detected in response to TGFbeta, and phosphorylation of JNK and ERK MAP kinases and IkappaBalpha was also decreased after BMP stimulation (Figure 4D and F and data not shown).
###end p 51
###begin title 52
Materials and methods
###end title 52
###begin title 53
Cells, plasmids, and antibodies
###end title 53
###begin p 54
###xml 133 134 133 134 <sc>L</sc>
###xml 282 283 282 283 <sc>L</sc>
###xml 1531 1555 1516 1540 <xref ref-type="supplementary-material" rid="S1">Supplementary Figure S5E</xref>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 456 460 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1437 1442 <span type="species:ncbi:10090">mouse</span>
HEK 293 cells (human kidney embryonic cells) were purchased from ATCC and cultured in DMEM medium (Cellgro) containing 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin. Primary and immortalized chondrocytes were cultured in DMEM-F12 medium (Cellgro) containing 2% FBS, 2 mM L-glutamine, 1% penicillin/streptomycin, 1% non-essential amino acids, Na-Selenate and transferrin. Plasmids for HA-ALK3, Myc-XIAP and HA-TAK1 (WT, DeltaN, and DeltaN/K63W), SV40 large T Ag, Myc-tagged TAK1 mutants, and GST-Smad1, 2, 3, and 4 were the gifts of Drs Hiroshi Shibuya, Kunihiro Matsumoto, Jun Ninomiya-Tsuji, Nobuyuki Tanaka, Xia-fan Wang, Ki-young Lee, and Zhijie Chang, respectively. Plasmid for LPCX-BMPR1B (Q203D) was purchased from Addgene. GST-Smad1 (AAVA) and TAK1 (WT and DeltaN/K63W) cDNAs were PCR amplified and cloned into pGEX vector (Amersham Pharmacia) and pHASE/PGK-PURO lentiviral vector, respectively. Antibodies used were anti-TAK1 (Millipore); anti-HA, anti-c-Myc, and anti-BMPR-1A (Santa Cruz); anti-Smad2, anti-phospho-Smad1/5/8, anti-phospho-Smad2 (S465/467), and anti-phospho-p38 (Cell Signaling); anti-Smad1 (Invitrogen); anti-Flag (M2, Sigma); anti-Smad4 (Abcam); anti-XIAP (Stressgen); and anti-GAPDH (Affinity Bioreagents). Cells were treated with rhBMP2/7 and mTGFbeta (R&D Systems) as indicated. To minimize interference of XIAP detection by the heavy and light chains of the immunoprecipitating BMPR1A antibody, mouse Trueblot ULTRA kit (eBioscience) was used for interaction analysis of BMPR1A with XIAP (Supplementary Figure S5E).
###end p 54
###begin title 55
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Generation of cartilage-specific TAK1-deficient mice
###end title 55
###begin p 56
###xml 0 4 0 4 <italic>Tak1</italic>
###xml 4 9 4 9 <sup>fl/fl</sup>
###xml 96 100 96 100 <italic>Tak1</italic>
###xml 100 106 100 106 <sup>fl/fl.</sup>
###xml 134 139 134 139 <italic>et al</italic>
###xml 122 145 122 145 <xref ref-type="bibr" rid="b25">Ovchinnikov <italic>et al</italic>, 2000</xref>
###xml 151 155 151 155 <italic>Tak1</italic>
###xml 155 161 155 161 <sup>fl/fl.</sup>
###xml 258 262 258 262 <italic>Tak1</italic>
###xml 262 267 262 267 <sup>fl/+.</sup>
###xml 281 285 281 285 <italic>Tak1</italic>
###xml 285 290 285 290 <sup>fl/fl</sup>
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
Tak1fl/fl mice were intercrossed with the earlier described Col2-cre deleter strain to generate Tak1fl/fl. Col2-cre mice (Ovchinnikov et al, 2000). As Tak1fl/fl. Col2-cre mice do not survive beyond 3 weeks of age, the line was maintained as an intercross of Tak1fl/+. Col2-cre and Tak1fl/fl mice. Animals were maintained in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were handled according to protocols approved by the institution's subcommittee on animal care (IACUC).
###end p 56
###begin title 57
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
Generation of mouse chondrocytes
###end title 57
###begin p 58
###xml 97 101 97 101 <italic>Tak1</italic>
###xml 101 106 101 106 <sup>fl/+.</sup>
###xml 120 124 120 124 <italic>Tak1</italic>
###xml 124 129 124 129 <sup>fl/fl</sup>
###xml 339 344 333 338 <italic>et al</italic>
###xml 332 350 326 344 <xref ref-type="bibr" rid="b8">Gosset <italic>et al</italic>, 2008</xref>
###xml 353 357 347 351 <italic>Tak1</italic>
###xml 357 363 351 357 <sup>fl/fl.</sup>
###xml 597 602 591 596 <italic>et al</italic>
###xml 587 608 581 602 <xref ref-type="bibr" rid="b14">Kobayashi <italic>et al</italic>, 2005</xref>
###xml 615 620 609 614 <italic>et al</italic>
###xml 610 626 604 620 <xref ref-type="bibr" rid="b32">Shim <italic>et al</italic>, 2005</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Chondroepiphyses were dissected from the long bones of day 1 newborn pups from the intercross of Tak1fl/+. Col2-cre and Tak1fl/fl mice. They were washed with PBS and incubated with 2 mg/ml collagenase P (Roche) for 2-4 h at 37degreesC. The cell suspension was plated in six-well plates containing DMEM-F12 supplemented with 2% FBS (Gosset et al, 2008). Tak1fl/fl. Col2-cre chondrocytes were identified by immunoblotting with TAK1 antibody and PCR genotyping using tail DNA. To immortalize primary chondrocytes, cells were stably transfected with linearized SV40 Large T antigen plasmid (Kobayashi et al, 2005; Shim et al, 2005) using Effectene trasnfection reagent (Qiagen).
###end p 58
###begin title 59
Skeletal preparation and histology
###end title 59
###begin p 60
###xml 107 119 107 119 <xref ref-type="bibr" rid="b22">McLeod, 1980</xref>
###xml 153 154 153 154 <sub>2</sub>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
The mineralization pattern of the skeleton was analysed at 20 days after birth using the method of McLeod (McLeod, 1980). Briefly, mice were killed by CO2 narcosis, skinned, eviscerated, and fixed in 95% ethanol. Then skeletons were stained by Alizarin red S/Alcian blue and sequentially cleared in 1% potassium hydroxide. For histological analyses, paraffin sections of bones were produced from E18.5, p0, and p20 mice. Limb tissues were dissected and fixed in 4% paraformaldehyde (PFA) in PBS. They were then decalcified by daily changes of 15% tetrasodium EDTA until soft and pliable. Tissues were dehydrated by passage through an ethanol series, cleared twice in xylene, embedded in paraffin, and sectioned. For morphological analyses, tissue sections were stained with haematoxylin and eosin.
###end p 60
###begin title 61
###xml 0 7 0 7 <italic>In situ</italic>
In situ hybridization
###end title 61
###begin p 62
###xml 4 11 4 11 <italic>in situ</italic>
###xml 1297 1308 <span type="species:ncbi:3704">horseradish</span>
For in situ hybridization, probe plasmids of Collagen X, IHH, and ID1 were kindly provided by Drs Bjorn Olsen, Beate Lanske, and Kuni Tsuji, respectively. DIG labelled probes were prepared using the DIG labelling kit (Roche) as per the manufacturer's instructions. Briefly, probes were purified by washing over a Ultrafree-MC filter column (Millipore). Tissue sections were prewarmed at 55degreesC and deparaffinized and rehydrated by passage through xylene and 100, 95, and 70% ethanol. Endogenous peroxidase activity was quenched by 15 min incubation in 3% hydrogen peroxide. Samples were treated with 10 mug/ml proteinase K for 15 min, 4% PFA for 5 min, and 0.25% acetic acid for 15 min before being dehydrated by passage through increasing concentrations of ethanol. Probe was added to the hybridization solution (50% formamide, 10 mM Tris-HCl pH 7.5, 200 mug/ml tRNA, 1 x Denhardt's, 10% Dextran sulphate, 600 mM NaCl, 0.25% SDS, 1 mM EDTA) and the solution prewarmed to 85degreesC before incubation with the tissue sections overnight. After incubation, sections were washed with standard sodium citrate buffer and treated with 10 mug/ml RNaseA in TNE buffer (10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA). DIG-labelled probe was then detected by immunostaining with anti-DIG-POD and streptadvidin-horseradish peroxidase.
###end p 62
###begin title 63
Immunohistochemistry
###end title 63
###begin p 64
###xml 105 112 105 112 <italic>in situ</italic>
###xml 311 315 <span type="species:ncbi:9925">goat</span>
For IHC, paraffin tissue sections were de-waxed and endogenous peroxidase quenched as in preparation for in situ hybridization. For anti-TAK1 staining, sections were then incubated with hyaluronidase. For anti-phospho-Smad1/5/8 staining, sections were heated in a pressure cooker. Sections were blocked with 3% goat serum, 1% BSA, 0.1% Triton X 100 in PBS for 1 h at room temperature and incubated with antibodies specific for TAK1 or phospho-Smad1/5/8 at 4degreesC overnight. Sections were then treated with TSA-biotin (Perkin Elmer) and streptavidin-HRP as per manufacturer's instructions, and HRP visualized with DAB (2,2'-diaminobenzidine tetrahydrochloride).
###end p 64
###begin title 65
Phosphopeptide analysis
###end title 65
###begin p 66
###xml 776 778 765 767 <sub>18</sub>
###xml 915 917 903 905 <sup>TM</sup>
HEK293 cells grown on three 10 cm petri dishes were transiently transfected using Effectene transfection reagent (Qiagen) with Flag-Smad1 together with either vector or HA-TAK1 (DeltaN). Flag-Smad1 protein was immunoprecipitated with anti-Flag conjugated agarose overnight at 4degreesC, eluted by Flag peptide, separated by SDS-PAGE, and stained with coomassie blue. Gel band containing Flag-Smad1 was excised and subjected to in-gel reduction and alkalyation followed by Lys-C or trypsin digestion. Digested peptides were extracted from the gel and analysed by liquid chromatography MS/MS (LC-MS/MS). Peptides were separated across a 37-min gradient ranging from 4 to 27% (v/v) acetonitrile in 0.1% (v/v) formic acid in a microcapillary (125 mum x 18 cm) column packed with C18 reverse-phase material (Magic C18AQ, 5 mum particles, 200 A pore size, Michrom Bioresources) and on-line analysed on The LTQ Orbitrap XLTM hybrid FTMS (Thermo Fisher Scientific). For each cycle, one full MS scan acquired on the Orbitrap at high mass resolution was followed by 10 MS/MS spectra on the linear ion trap XL from the 10 most abundant ions. MS/MS spectra were searched using the Sequest algorithm against Smad1 protein with dynamic modification of methionine oxidation and serine, threonine and tyrosine phosphorylation. All peptide matches were filtered based on mass deviation, tryptic state, XCorr, and dCn and confirmed by manual validation.
###end p 66
###begin title 67
Luciferase reporter assay
###end title 67
###begin p 68
###xml 217 224 214 221 <italic>Renilla</italic>
Immortalized chondrocytes grown on 12-well plates were transiently transfected using Effectene transfection reagent (Qiagen) with the BMP (Tlx2-lux) or TGFbeta-dependent reporter construct (3TP-luc) together with the Renilla luciferase vector (Promega). Total DNA concentration in each experiment was maintained by adding the appropriate control vector to the DNA mixture. At 24 h after transfection, cells were serum starved for 12 h before treatment with BMP2/7 or TGFbeta. After 24 h, cells were lysed and luciferase activity was measured using the dual luciferase assay kit (Promega).
###end p 68
###begin title 69
###xml 0 8 0 8 <italic>In vitro</italic>
In vitro kinase assay
###end title 69
###begin p 70
###xml 4 12 4 12 <italic>in vitro</italic>
###xml 790 791 771 772 <sub>2</sub>
###xml 596 602 <span type="species:ncbi:9986">Rabbit</span>
For in vitro kinase assays, immortalized chondrocytes grown on 10 cm petri dishes were serum starved for 12 h before treatment with either BMP2/7 (100 ng/ml) or TGFbeta (2 ng/ml) and then lysed in TNT lysis buffer (1% triton X-100, 50 mM Tris, pH 7.5, 200 mM NaCl, protease inhibitors). Alternatively, HEK293 cells were transiently transfected with vector, HA-tagged TAK1 (DeltaN or CI). Protein levels in each lysate were determined using a Bio-Rad protein assay kit (Bio-Rad) and then normalized among the samples. Protein from lysates was immunoprecipitated using either anti-TAK1 antibody or Rabbit IgG and protein A-sepharose or anti-HA conjugated agarose overnight at 4degreesC and precipitates were incubated for 15 min at 30degreesC in kinase buffer (20 mM HEPES, pH 7.5, 20 mM MgCl2, 1 mM EDTA, 2 mM NaF, 2 mM-glycerophosphate, 1 mM DTT, 10 muM ATP) containing appropriate GST-fused Smad proteins and 10 muCi of [gamma32P]ATP (PerkinElmer). The substrates were then precipitated using glutathione-agarose (Novagen), resolved by SDS-PAGE and phosphorylated proteins were visualized by autoradiography.
###end p 70
###begin title 71
Supplementary Material
###end title 71
###begin p 72
Supplementary Information
###end p 72
###begin p 73
Review Process File
###end p 73
###begin p 74
We thank Drs Marc Wein and Vicki Rosen for their thoughtful review of the manuscript, Dorothy Zhang, Michelle Schweitzer and Pamela Okerholm for technical assistance and Dallas Jones for helpful discussions. We also thank the many individuals who provided valuable reagents. This work was supported by National Institutes of Health grant AI29673 and HD055601 (LHG) and NIH HL52555 (MDS); JS was supported by an Arthritis Foundation postdoctoral fellowship.
###end p 74
###begin p 75
The authors declare that they have no conflict of interest.
###end p 75
###begin article-title 76
TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling.
###end article-title 76
###begin article-title 77
Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones.
###end article-title 77
###begin article-title 78
Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis.
###end article-title 78
###begin article-title 79
###xml 18 22 <span type="species:ncbi:10090">mice</span>
SMAD 8 binding to mice Msx1 basal promoter is required for transcriptional activation.
###end article-title 79
###begin article-title 80
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects.
###end article-title 80
###begin article-title 81
Smad-dependent and Smad-independent pathways in TGF-beta family signalling.
###end article-title 81
###begin article-title 82
Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal.
###end article-title 82
###begin article-title 83
###xml 35 41 <span type="species:ncbi:10090">murine</span>
Primary culture and phenotyping of murine chondrocytes.
###end article-title 83
###begin article-title 84
BMP signaling stimulates chondrocyte maturation and the expression of Indian hedgehog.
###end article-title 84
###begin article-title 85
###xml 133 139 <span type="species:ncbi:10090">murine</span>
Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors.
###end article-title 85
###begin article-title 86
MADR1, a MAD-related protein that functions in BMP2 signaling pathways.
###end article-title 86
###begin article-title 87
###xml 66 73 66 73 <italic>in vivo</italic>
The TGF beta activated kinase TAK1 regulates vascular development in vivo.
###end article-title 87
###begin article-title 88
Developmental patterning in chondrocytic cultures by morphogenic gradients: BMP induces expression of indian hedgehog and noggin.
###end article-title 88
###begin article-title 89
Hrs, a mammalian master molecule in vesicular transport and protein sorting, suppresses the degradation of ESCRT proteins signal transducing adaptor molecule 1 and 2.
###end article-title 89
###begin article-title 90
Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis.
###end article-title 90
###begin article-title 91
Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1.
###end article-title 91
###begin article-title 92
The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase.
###end article-title 92
###begin article-title 93
Developmental regulation of the growth plate.
###end article-title 93
###begin article-title 94
Essential role of TAK1 in thymocyte development and activation.
###end article-title 94
###begin article-title 95
MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling.
###end article-title 95
###begin article-title 96
TGF-beta signal transduction.
###end article-title 96
###begin article-title 97
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S.
###end article-title 97
###begin article-title 98
Id: a target of BMP signaling.
###end article-title 98
###begin article-title 99
TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis.
###end article-title 99
###begin article-title 100
###xml 81 96 <span type="species:ncbi:10090">transgenic mice</span>
Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice.
###end article-title 100
###begin article-title 101
Balancing BMP signaling through integrated inputs into the Smad1 linker.
###end article-title 101
###begin article-title 102
Essential function for the kinase TAK1 in innate and adaptive immune responses.
###end article-title 102
###begin article-title 103
TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells.
###end article-title 103
###begin article-title 104
Transforming growth factor-beta-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis.
###end article-title 104
###begin article-title 105
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis.
###end article-title 105
###begin article-title 106
###xml 48 55 <span type="species:ncbi:8355">Xenopus</span>
Role of TAK1 and TAB1 in BMP signaling in early Xenopus development.
###end article-title 106
###begin article-title 107
###xml 83 90 83 90 <italic>in vivo</italic>
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo.
###end article-title 107
###begin article-title 108
The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.
###end article-title 108
###begin article-title 109
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily.
###end article-title 109
###begin article-title 110
###xml 76 80 <span type="species:ncbi:10090">mice</span>
TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice.
###end article-title 110
###begin article-title 111
BMP signaling in skeletal development.
###end article-title 111
###begin article-title 112
The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function.
###end article-title 112
###begin article-title 113
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse.
###end article-title 113
###begin article-title 114
Novel regulators of bone formation: molecular clones and activities.
###end article-title 114
###begin article-title 115
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway.
###end article-title 115
###begin article-title 116
XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway.
###end article-title 116
###begin article-title 117
Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction.
###end article-title 117
###begin article-title 118
TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta.
###end article-title 118
###begin article-title 119
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb.
###end article-title 119
###begin article-title 120
Multiple functions of BMPs in chondrogenesis.
###end article-title 120
###begin article-title 121
###xml 82 89 82 89 <italic>in vivo</italic>
Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo.
###end article-title 121
###begin article-title 122
BMPs regulate multiple aspects of growth-plate chondrogenesis through opposing actions on FGF pathways.
###end article-title 122
###begin article-title 123
Smad4 is required for the normal organization of the cartilage growth plate.
###end article-title 123
###begin p 124
###xml 43 44 43 44 <bold>A</bold>
###xml 142 146 142 146 <italic>Tak1</italic>
###xml 146 151 146 151 <sup>fl/fl</sup>
###xml 156 160 156 160 <italic>Tak1</italic>
###xml 160 164 160 164 <sup>col2</sup>
###xml 315 316 315 316 <bold>B</bold>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
Expression of TAK1 in the proximal tibia. (A) Immunohistochemistry for TAK1 showing expression in a coronal section of the proximal tibias of Tak1fl/fl and Tak1col2 mice. Secondary centres of ossification are indicated with arrows, hypertrophic chondrocytes in the terminal growth plate are indicated with an 'H'. (B) High power of the indicated areas of (A), showing TAK1 expression in prehypertrophic and hypertrophic chondrocytes.
###end p 124
###begin p 125
###xml 56 57 56 57 <bold>A</bold>
###xml 95 99 95 99 <italic>Tak1</italic>
###xml 99 104 99 104 <sup>fl/fl</sup>
###xml 109 113 109 113 <italic>Tak1</italic>
###xml 113 117 113 117 <sup>col2</sup>
###xml 172 176 172 176 <italic>Tak1</italic>
###xml 176 181 176 181 <sup>fl/fl</sup>
###xml 186 190 186 190 <italic>Tak1</italic>
###xml 190 194 190 194 <sup>col2</sup>
###xml 249 253 249 253 <italic>Tak1</italic>
###xml 253 257 253 257 <sup>col2</sup>
###xml 280 281 280 281 <bold>B</bold>
###xml 330 334 330 334 <italic>Tak1</italic>
###xml 334 339 334 339 <sup>fl/fl</sup>
###xml 344 348 344 348 <italic>Tak1</italic>
###xml 348 352 348 352 <sup>col2</sup>
###xml 440 444 440 444 <italic>Tak1</italic>
###xml 444 449 444 449 <sup>fl/fl</sup>
###xml 454 458 454 458 <italic>Tak1</italic>
###xml 458 462 458 462 <sup>col2</sup>
###xml 491 495 491 495 <italic>Tak1</italic>
###xml 495 499 495 499 <sup>col2</sup>
###xml 607 608 607 608 <bold>C</bold>
###xml 610 617 610 617 <italic>In situ</italic>
###xml 697 701 697 701 <italic>Tak1</italic>
###xml 701 706 701 706 <sup>fl/fl</sup>
###xml 711 715 711 715 <italic>Tak1</italic>
###xml 715 719 715 719 <sup>col2</sup>
###xml 784 785 784 785 <bold>D</bold>
###xml 868 872 868 872 <italic>Tak1</italic>
###xml 872 877 872 877 <sup>fl/fl</sup>
###xml 882 886 882 886 <italic>Tak1</italic>
###xml 886 890 886 890 <sup>col2</sup>
###xml 1016 1017 1016 1017 <bold>E</bold>
###xml 1113 1117 1113 1117 <italic>Tak1</italic>
###xml 1117 1122 1117 1122 <sup>fl/fl</sup>
###xml 1127 1131 1127 1131 <italic>Tak1</italic>
###xml 1131 1135 1131 1135 <sup>col2</sup>
###xml 1165 1169 1165 1169 <italic>Tak1</italic>
###xml 1169 1173 1169 1173 <sup>col2</sup>
###xml 1181 1182 1181 1182 <bold>F</bold>
###xml 1222 1226 1222 1226 <italic>Tak1</italic>
###xml 1226 1231 1226 1231 <sup>fl/fl</sup>
###xml 1236 1240 1236 1240 <italic>Tak1</italic>
###xml 1240 1244 1240 1244 <sup>col2</sup>
###xml 1323 1327 1323 1327 <italic>Tak1</italic>
###xml 1327 1332 1327 1332 <sup>fl/fl</sup>
###xml 1337 1341 1337 1341 <italic>Tak1</italic>
###xml 1341 1345 1341 1345 <sup>col2</sup>
###xml 1352 1356 1352 1356 <italic>Tak1</italic>
###xml 1356 1360 1356 1360 <sup>col2</sup>
###xml 1520 1521 1520 1521 <bold>G</bold>
###xml 1624 1628 1624 1628 <italic>Tak1</italic>
###xml 1628 1633 1628 1633 <sup>fl/fl</sup>
###xml 1638 1642 1638 1642 <italic>Tak1</italic>
###xml 1642 1646 1642 1646 <sup>col2</sup>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 891 895 <span type="species:ncbi:10090">mice</span>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
###xml 1174 1178 <span type="species:ncbi:10090">mice</span>
###xml 1245 1249 <span type="species:ncbi:10090">mice</span>
###xml 1346 1350 <span type="species:ncbi:10090">mice</span>
###xml 1361 1365 <span type="species:ncbi:10090">mice</span>
###xml 1647 1651 <span type="species:ncbi:10090">mice</span>
Abnormal cartilage development of TAK1-deficient mice. (A) Skeletal preparations of 3 week old Tak1fl/fl and Tak1col2 mice (upper panels). X-ray of the skull of 3 week old Tak1fl/fl and Tak1col2 mice, showing doming of the skull and malocclusion in Tak1col2 mice (lower panels). (B) Histological analysis of the proximal tibia of Tak1fl/fl and Tak1col2 mice. Haematoxylin and eosin-stained sections through the proximal tibia of 3 week old Tak1fl/fl and Tak1col2 mice. The proximal tibia of Tak1col2 mice is smaller and shows impaired formation of secondary ossification centres (indicated with an arrow). (C) In situ hybridization for Collagen X〈(ColX) in the proximal humerus of E16.5 and E18.5 Tak1fl/fl and Tak1col2 mice, demonstrating similar extent of chondrocyte hypertrophy. (D) PCNA (top panel) and TUNEL (bottom panel) staining on the chondroepiphyses of p0 Tak1fl/fl and Tak1col2 mice, demonstrating a decrease in PCNA-positive cells and an increase in TUNEL-positive terminal hypertrophic chondrocytes. (E) X-rays and alizarin red/alcian blue stained skeletal preparations of the elbows of 3 week old Tak1fl/fl and Tak1col2 mice, showing dislocation in Tak1col2 mice. (F) Histological analysis of the elbow of Tak1fl/fl and Tak1col2 mice. Haematoxylin and eosin-stained sections through elbows of p20 and E14.5 Tak1fl/fl and Tak1col2 mice. Tak1col2 mice show an overgrowth of the cartilage on the distal humerus and a widening of the proximal radius. The humerus (H), radius (R), and ulna (U) are labelled. (G) High-power view of the ankle of alizarin red/alcian blue stained skeletal preparations of 3 week old Tak1fl/fl and Tak1col2 mice, showing fusion of the tarsal bones and medial dislocation of the phalanges. C, intermediate cuneiform; LC, lateral cuneiform; CU, cuboid; NC, navicular; CA, calcaneus; TA, talus.
###end p 125
###begin p 126
###xml 48 49 48 49 <bold>A</bold>
###xml 170 174 170 174 <italic>Tak1</italic>
###xml 174 179 174 179 <sup>fl/fl</sup>
###xml 184 188 184 188 <italic>Tak1</italic>
###xml 188 192 188 192 <sup>col2</sup>
###xml 332 333 332 333 <bold>B</bold>
###xml 399 403 399 403 <italic>Tak1</italic>
###xml 403 408 403 408 <sup>fl/fl</sup>
###xml 413 417 413 417 <italic>Tak1</italic>
###xml 417 421 417 421 <sup>col2</sup>
###xml 499 500 499 500 <bold>C</bold>
###xml 502 509 502 509 <italic>In situ</italic>
###xml 628 632 624 628 <italic>Tak1</italic>
###xml 632 637 628 633 <sup>fl/fl</sup>
###xml 642 646 638 642 <italic>Tak1</italic>
###xml 646 650 642 646 <sup>col2</sup>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
Reduced BMP signalling in TAK1-deficient mice. (A) Immunohistochemistry for phosphorylation of BMP-responsive Smad proteins. Coronal sections of the proximal tibia of P0 Tak1fl/fl and Tak1col2 pups were stained with anti-phospho-Smad1/5/8 antibody. Hypertrophic chondrocytes in the terminal growth plate are indicated with an 'H'. (B) Primary chondrocytes were isolated from cartilage tissues of p0 Tak1fl/fl and Tak1col2 mice, cultured for 3 days, and immunoblotted with the indicated antibodies. (C) In situ hybridization for IHH, Patched, ID1, and Collagen Xalpha (ColX). Coronal sections of the proximal tibia of 3 week old Tak1fl/fl and Tak1col2 mice were probed for the expression of the indicated mRNAs. The hypertrophic region of the growth plate is shown.
###end p 126
###begin p 127
###xml 56 57 56 57 <bold>A</bold>
###xml 141 145 141 145 <italic>Tak1</italic>
###xml 145 150 145 150 <sup>fl/fl</sup>
###xml 155 159 155 159 <italic>Tak1</italic>
###xml 159 163 159 163 <sup>col2</sup>
###xml 283 284 283 284 <bold>B</bold>
###xml 286 287 286 287 <bold>C</bold>
###xml 396 403 396 403 <italic>Renilla</italic>
###xml 638 645 635 642 <italic>Renilla</italic>
###xml 656 657 653 654 <bold>D</bold>
###xml 659 660 656 657 <bold>E</bold>
###xml 675 679 672 676 <italic>Tak1</italic>
###xml 679 684 676 681 <sup>fl/fl</sup>
###xml 689 693 686 690 <italic>Tak1</italic>
###xml 693 697 690 694 <sup>col2</sup>
###xml 1019 1020 1016 1017 <bold>F</bold>
###xml 1035 1039 1032 1036 <italic>Tak1</italic>
###xml 1039 1044 1036 1041 <sup>fl/fl</sup>
###xml 1049 1053 1046 1050 <italic>Tak1</italic>
###xml 1053 1057 1050 1054 <sup>col2</sup>
Reduced BMP signalling in TAK1-deficient chondrocytes. (A) Real time-PCR analysis for BMP-responsive gene induction in primary chondrocytes. Tak1fl/fl and Tak1col2 chondrocytes were treated with or without BMP2/7 (100 ng/ml) for 6 h and total RNA was extracted for RT-PCR analysis. (B, C) Immortalized chondrocytes were transfected with either Tlx2-lux (upper panel) or 3TP-luc (lower panel) and Renilla luciferase vectors. Cells were serum starved for 12 h before treatment with BMP2/7 (upper panel) or TGFbeta (lower panel), and then analysed for luciferase activity. Results are expressed as relative luciferase activity normalized by Renilla control. (D, E) Immortalized Tak1fl/fl and Tak1col2 chondrocytes were serum starved for 12 h before BMP2/7 (100 ng/ml) stimulation for the indicated times, and then immunoblotted with antibodies specific to phospho-Smad1/5/8 (D), phospho-Erk1/2, or phospho-Jnk1/2 (E). Immunoblotting analysis with antibodies specific to GAPDH (D) or Hsp90 (E) was performed as a control. (F) Immortalized Tak1fl/fl and Tak1col2 chondrocytes were serum starved for 12 h before TGFbeta (2 ng/ml) stimulation for the indicated times, and then immunoblotted with antibodies specific to phospho-Smad2 and phospho-p38. Immunoblotting analysis with anti-GAPDH antibody was performed as a control.
###end p 127
###begin p 128
###xml 64 65 64 65 <bold>A</bold>
###xml 334 342 334 342 <italic>in vitro</italic>
###xml 355 357 355 357 <sup>35</sup>
###xml 474 482 474 482 <italic>in vitro</italic>
###xml 495 497 495 497 <sup>35</sup>
###xml 529 530 529 530 <bold>B</bold>
###xml 870 871 870 871 <bold>C</bold>
###xml 1237 1245 1233 1241 <italic>in vitro</italic>
###xml 1261 1262 1257 1258 <bold>D</bold>
###xml 1264 1265 1260 1261 <bold>E</bold>
###xml 1684 1692 1671 1679 <italic>in vitro</italic>
###xml 764 770 <span type="species:ncbi:9986">Rabbit</span>
TAK1 is an upstream kinase of Smad proteins in BMP signalling. (A) Direct interaction of TAK1 with BMP-responsive Smad proteins. HEK293 cells were transfected with Flag-Smad1, 5, and 8, and lysed and immunoprecipitated with anti-Flag-conjugated beads. The interactions were tested by Flag pull down assays with Flag-Smad proteins and in vitro translated, 35S-labelled TAK1 (upper panel). Alternatively, GST pull down analysis was performed using either GST or GST-Smad1 and in vitro translated, 35S-labelled TAK1 (lower panel). (B) Endogenous interaction of TAK1 with BMP-responsive Smad proteins. Immortalized chondrocytes were serum starved before BMP2/7 (100 ng/ml) stimulation for the indicated times, and then cells were lysed, immunoprecipitated with either Rabbit IgG or anti-TAK1 antibody and protein A agarose, and immunoblotted with the indicated antibodies. (C) TAK1-induced phosphorylation of Smad proteins. HEK293 cells were transfected with either vector control, constitutively active HA-TAK1 (DeltaN), or catalytically inactive HA-TAK1 (CI) and immunoprecipitated with anti-HA antibody and protein G agarose. The immunoprecipitates were mixed with GST, GST-Smad1, Smad2, or Mkk6, and TAK1 kinase activity was analysed by in vitro kinase assay. (D, E) TAK1 activates BMP-responsive Smad1 more efficiently than TGFbeta-responsive Smad2. Immortalized wt chondrocytes were serum starved for 12 h before treatment with BMP2/7 (100 ng/ml) or TGFbeta (2 ng/ml) for the indicated time and then immunoprecipitated with anti-TAK1 antibody. The immunoprecipitates were mixed with GST-Smad1 (BMP2/7), GST-Smad2 (TGFbeta) (D), or GST-Mkk6 (E). TAK1 kinase activity was analysed by in vitro kinase assay.
###end p 128
###begin p 129
###xml 56 57 56 57 <bold>A</bold>
###xml 432 433 428 429 <bold>B</bold>
###xml 648 649 640 641 <bold>C</bold>
###xml 913 921 901 909 <italic>in vitro</italic>
###xml 937 938 925 926 <bold>D</bold>
###xml 1206 1214 1194 1202 <italic>in vitro</italic>
###xml 1230 1231 1218 1219 <bold>E</bold>
###xml 1536 1544 1524 1532 <italic>in vitro</italic>
Identification of Smad1 phosphorylation sites by TAK1. (A) Phosphopeptide analysis of Smad1. HEK293 cells were transfected with Flag-Smad1 together with either vector or HA-TAK1 (DeltaN). After immunoprecipitation with anti-Flag conjugated agarose, Smad1 proteins were eluted by Flag peptide, separated by SDS-PAGE, and stained with Coomassie blue (upper panel). The predicted proteolytic digestion pattern of Smad1 (lower panel). (B) Smad1 phosphorylation by TAK1. HEK293 cells were transfected with Flag-Smad1 together with either vector, HA-TAK1 (DeltaN), or HA-BMPR1B (Q203D). Cells were lysed and immunoblotted with the indicated antibodies. (C) TAK1-mediated phosphorylation of Smad1 at the C-terminal serines. HEK293 cells were transfected with either vector or HA-TAK1 (DeltaN), and the immunoprecipitates were mixed with wt GST-Smad1 (WT) or mutant GST-Smad1 (AAVA). TAK1 kinase activity was analysed by in vitro kinase assay. (D) BMPR1B-mediated phosphorylation of Smad1 at the C-terminal serines. HEK293 cells were transfected with either vector or HA-BMPR1B (Q203D) and the immunoprecipitates were mixed with wt GST-Smad1 (WT) or mutant GST-Smad1 (AAVA). BMPR1B kinase activity was analysed by in vitro kinase assay. (E) Immortalized chondrocytes were serum starved for 12 h before BMP2/7 (100 ng/ml) stimulation for 20 min. The TAK1 immunoprecipitates were washed under stringent conditions to minimize contamination by other endogenous proteins, mixed with GST-Smad1 (WT or AAVA), and TAK1 kinase activity was analysed by in vitro kinase assay.
###end p 129
###begin p 130
###xml 55 56 55 56 <bold>A</bold>
###xml 58 59 58 59 <bold>B</bold>
###xml 645 646 645 646 <bold>C</bold>
TAK1 kinase activity is important for BMP signalling. (A, B) Immortalized chondrocytes were infected either by vector control, TAK1 (WT), or TAK1 (CI) lentivirues and selected in puromycin-containing medium. (A) Cells were serum starved for 12 h before BMP2/7 (100 ng/ml) stimulation for the indicated time and immunoblotted with antibodies specific to phospho-Smad1/5/8 and phospho-p38. Immunoblotting with anti-Hsp90 and -TAK1 antibodies were performed for protein loading control and TAK1 expression, respectively. (B) Alternatively, cells were unstimulated or stimulated with BMP2/7 for 6 h and total RNA was extracted for RT-PCR analysis. (C) Schematic model of TAK1 function in BMP signalling pathways.
###end p 130
###begin p 131
###xml 25 30 <span type="species:ncbi:9606">human</span>
Proteolytic digestion of human Smad1 by Trypsin
###end p 131
###begin p 132
###xml 0 1 0 1 <sup>*</sup>
*Phosphorylation.
###end p 132
###begin p 133
###xml 25 30 <span type="species:ncbi:9606">human</span>
Proteolytic digestion of human Smad1 by Lys-C
###end p 133
###begin p 134
###xml 0 1 0 1 <sup>*</sup>
*Phosphorylation.
###end p 134

